var title_f5_59_6064="OCT catheter";
var content_f5_59_6064=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F50024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F50024&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 488px\">",
"   <div class=\"ttl\">",
"    Optical coherence tomography (OCT) catheter",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 468px; height: 199px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    OCT catheter shown exiting the accessory channel of a gastroscope.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Shai Friedland, MD and Jacques Van Dam, MD, PhD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6064=[""].join("\n");
var outline_f5_59_6064=null;
var title_f5_59_6065="Cytotoxicity assays II";
var content_f5_59_6065=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F68336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F68336&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 502px\">",
"   <div class=\"ttl\">",
"    Flow cytometry based cytotoxicity assay",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 482px; height: 225px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Detection of perforin in NK cells.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6065=[""].join("\n");
var outline_f5_59_6065=null;
var title_f5_59_6066="Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)";
var content_f5_59_6066=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/86547\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/2/40997\">",
"         Lymphatic system in women",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/55/4979\">",
"          Sentinel node biopsy for breast cancer",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?2/19/2357\">",
"         Patient information: Breast cancer (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?18/59/19379\">",
"         Patient information: Breast cancer screening (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?5/62/6115\">",
"         Patient information: Common breast problems (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?11/56/12167\">",
"         Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/40/36481\">",
"         Patient information: Breast cancer screening (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Sentinel lymph node biopsy for breast cancer (The Basics)",
"    </div>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H702671576\">",
"      <span class=\"h1\">",
"       What is a sentinel lymph node biopsy for breast cancer?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A sentinel lymph node biopsy for breast cancer is an operation to check if your breast cancer has spread to your lymph nodes.",
"     </p>",
"     <p>",
"      Lymph nodes are bean-shaped organs found all over the body, including the armpits, neck, and groin. They are part of a network of vessels called the called the &ldquo;lymphatic system&rdquo; that carries a clear fluid called &ldquo;lymph&rdquo; (",
"      <a class=\"graphic graphic_figure graphicRef86801 \" href=\"UTD.htm?40/2/40997\">",
"       figure 1",
"      </a>",
"      ). When breast cancer cells spread, they usually travel through the lymph to one or more lymph nodes (called sentinel lymph nodes) in the armpits.",
"     </p>",
"     <p>",
"      During a sentinel lymph node biopsy (also called &ldquo;SLNB&rdquo;) a surgeon finds, takes out, and checks the sentinel lymph nodes for cancer cells. Knowing whether cancer is in the sentinel lymph nodes helps your doctor choose the right treatment for your breast cancer.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H702671591\">",
"      <span class=\"h1\">",
"       What happens during an SLNB?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The operation is usually done under general anesthesia. This means you will get medicines through a small tube into a vein (called an &ldquo;IV&rdquo;) and gases that you breathe through a mask to make you unconscious.",
"     </p>",
"     <p>",
"      Doctors use 2 different techniques to find the sentinel node (",
"      <a class=\"graphic graphic_figure graphicRef86545 \" href=\"UTD.htm?4/55/4979\">",
"       figure 2",
"      </a>",
"      ):",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blue dye &ndash; For this technique, the doctor injects blue dye into your breast near the cancer after you are unconscious in the operating room. The dye travels through the lymph and turns the sentinel node blue.",
"       </li>",
"       <li>",
"        A radioactive substance &ndash; For this technique, the doctor injects a radioactive substance into your breast near the cancer and the colored area around your nipple, before you go to the operating room. Then, after you are unconscious, the doctor uses a special device that finds radioactive substances to locate the sentinel lymph node.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Most surgeons use just 1 technique, but some use both. After finding the sentinel nodes, the surgeon makes a small cut to take them out and sends them to a lab. A different doctor then checks them for cancer cells.",
"     </p>",
"     <p>",
"      Most people do not have cancer in their sentinel lymph nodes. But if they do, the surgeon might take out other nearby nodes to check them as well.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H702671608\">",
"      <span class=\"h1\">",
"       What happens after an SLNB?",
"      </span>",
"      &nbsp;&mdash;&nbsp;After an SLNB, you might have pain, bruising, bleeding, or get an infection. Your doctor will prescribe pain relievers or other medicines to treat any symptoms.",
"     </p>",
"     <p>",
"      If your doctor used blue dye, part of your breast will be blue until all of the dye disappears from your body. Your urine will also turn green for 1 day.",
"     </p>",
"     <p>",
"      In rare cases, people are allergic to the dye used for SLNB. Your doctor will tell you about this risk and answer any questions you have before the operation. The allergic reaction happens in the operating room and is treated right away with medicines given through an IV.",
"     </p>",
"     <p>",
"      If your doctor used a radioactive substance, the amount of radioactivity is very low and not harmful. It leaves your body quickly through your urine. You are not &ldquo;radioactive&rdquo; or dangerous to other people near you.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H702671625\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=see_link\">",
"       Patient information: Breast cancer screening (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=see_link\">",
"       Patient information: Breast cancer (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=see_link\">",
"       Patient information: Common breast problems (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=see_link\">",
"       Patient information: Breast cancer screening (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=see_link\">",
"       Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?5/59/6066?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 86547 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-217.117.136.88-C2C11C53A9-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6066=[""].join("\n");
var outline_f5_59_6066=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H702671576\">",
"      What is a sentinel lymph node biopsy for breast cancer?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H702671591\">",
"      What happens during an SLNB?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H702671608\">",
"      What happens after an SLNB?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H702671625\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/86547\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/2/40997\">",
"      Lymphatic system in women",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/55/4979\">",
"       Sentinel node biopsy for breast cancer",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?2/19/2357?source=related_link\">",
"      Patient information: Breast cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?11/56/12167?source=related_link\">",
"      Patient information: Breast cancer guide to diagnosis and treatment (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?35/40/36481?source=related_link\">",
"      Patient information: Breast cancer screening (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?18/59/19379?source=related_link\">",
"      Patient information: Breast cancer screening (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?5/62/6115?source=related_link\">",
"      Patient information: Common breast problems (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_59_6067="Technetium Tc 99m Diethylene Triamine Penta-Acetic Acid: Patient drug information";
var content_f5_59_6067=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Technetium Tc 99m Diethylene Triamine Penta-Acetic Acid: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/36/28227?source=see_link\">",
"     see \"Technetium Tc 99m Diethylene Triamine Penta-Acetic Acid: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F13734606\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      DRAXIMAGE&reg; DTPA",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F13825494\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560752",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with a special imaging test.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F13825493\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3654513",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to technetium Tc 99m diethylene triamine penta-acetic acid or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F13825497\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F13825498\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3560985",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Facial swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698134",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High blood pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698328",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Unsafe allergic effects may rarely happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F13825499\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F13825496\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F13825501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 83363 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-118.195.65.247-661AF214C7-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6067=[""].join("\n");
var outline_f5_59_6067=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13734606\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825494\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825493\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825497\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825498\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825499\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825496\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13825501\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/36/28227?source=related_link\">",
"      Technetium Tc 99m Diethylene Triamine Penta-Acetic Acid: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_59_6068="Poison ivy";
var content_f5_59_6068=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Poison ivy (Beyond the Basics)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/59/6068/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/59/6068/contributors\">",
"     Lori Prok, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/59/6068/contributors\">",
"     Thomas McGovern, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/59/6068/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/59/6068/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/59/6068/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/59/6068/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/59/6068/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;When the skin comes in direct contact with an irritating or allergy-causing substance, contact dermatitis can develop. Exposure to poison ivy, poison oak, and poison sumac cause more cases of allergic contact dermatitis than all other plant families combined.",
"   </p>",
"   <p>",
"    People of all ethnicities and skin types are at risk for developing poison ivy dermatitis. The severity of the reaction tends to decrease with age, especially in people who have had mild reactions in the past. People in occupations such as firefighting, forestry, and farming are at a higher risk of poison ivy dermatitis because of repeated exposure to toxic plants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     POISON IVY DERMATITIS CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poison ivy, poison oak, and poison sumac plants all contain a compound called urushiol, which is a light, colorless oil that is found on the fruit, leaves, stem, root, and sap of the plant. When urushiol is exposed to air, it turns brown and the plant leaves develop small black spots.",
"   </p>",
"   <p>",
"    There are several ways that you can be exposed to urushiol:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      By touching the sap or rubbing against the leaves of the toxic plant at any time of year",
"     </li>",
"     <li>",
"      By touching something that has urushiol on it, such as animal fur or garden tools",
"     </li>",
"     <li>",
"      By breathing in smoke when toxic plants are burned",
"     </li>",
"     <li>",
"      Ginkgo fruit and the skin of mangoes also contain urushiol and can produce symptoms similar to poison ivy dermatitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     IDENTIFYING POISON IVY",
"    </span>",
"    &nbsp;&mdash;&nbsp;\"Leaves of three, let them be\" is a phrase often used to identify plants that cause poison ivy dermatitis. Generally, poison ivy and poison oak have three leaflets per leaf with flowering branches on a single stem. Poison sumac has five, seven, or more leaflets per leaf that angle upward toward the top of the stem (",
"    <a class=\"graphic graphic_figure graphicRef79136 \" href=\"UTD.htm?40/20/41282\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef82260 graphicRef59717 graphicRef68304 \" href=\"UTD.htm?36/63/37882\">",
"     picture 1A-C",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Poison ivy plants produce a green or off-white fruit in autumn, and in some cases, black dots form on the plants' leaves. It is not always possible to identify the plant by the leaves alone since the appearance can vary depending upon the season, growth cycle, region, and climate.",
"   </p>",
"   <p>",
"    Poison ivy, oak, and sumac plants grow in many areas across the United States and throughout the world. East of the Rocky Mountains, poison ivy commonly grows as a climbing vine. In the Rocky Mountain area and west, poison ivy tends to grow low to the ground as a shrub. Poison oak most often grows west of the Rocky Mountains, and poison sumac inhabits boggy areas in the southeastern part of the United States. The plants are not usually found in areas at high elevations or in desert climates.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     POISON IVY SIGNS AND SYMPTOMS",
"    </span>",
"    &nbsp;&mdash;&nbsp;After contact with urushiol, approximately 50 percent of people develop signs and symptoms of poison ivy dermatitis. The symptoms and severity differ from person to person.",
"   </p>",
"   <p>",
"    The most common signs and symptoms of poison ivy dermatitis are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Intense itching",
"     </li>",
"     <li>",
"      Skin swelling",
"     </li>",
"     <li>",
"      Skin redness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These symptoms usually develop within four hours to four days after exposure to the urushiol. After the initial symptoms, you will develop fluid-filled blisters in a line or streak-like pattern. The symptoms are worst within 1 to 14 days after touching the plant, but can develop up to 21 days later if you have never been exposed to urushiol before.",
"   </p>",
"   <p>",
"    The blisters can occur at different times in different people; blisters can develop on the arms several days after blisters on the hands developed. This does not mean that the reaction is spreading from one area of the body to the other. The fluid that leaks from blisters does not spread the rash. Poison ivy dermatitis is not contagious and cannot be passed from person to person. However, urushiol can be carried under fingernails and on clothes; if another person comes in contact with the urushiol, they can develop poison ivy dermatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     POISON IVY DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poison ivy is usually diagnosed based upon how your skin looks. Further testing is not usually necessary.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     POISON IVY TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Poison ivy dermatitis usually resolves within one to three weeks without treatment. Treatments that may help relieve the itching, soreness, and discomfort caused by poison ivy dermatitis include:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Skin treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;For some people, adding oatmeal to a bath, applying cool wet compresses, and applying",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/11/33969?source=see_link\">",
"     calamine lotion",
"    </a>",
"    may help to relieve itching. Once the blisters begin weeping fluid, astringents containing aluminum acetate (Burrow's solution) and Domeboro may help to relieve the rash.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Antihistamines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antihistamines",
"    <strong>",
"     do not",
"    </strong>",
"    help to relieve itching caused by poison ivy dermatitis. Some antihistamines make you sleepy while others do not. The ones that make you sleepy (eg,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?24/60/25537?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    [sample brand name Benadryl&reg;]) can help you to ignore the itch while sleeping.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Steroid creams",
"    </span>",
"    &nbsp;&mdash;&nbsp;Steroid creams may be helpful if they are used during the first few days after symptoms develop. Low potency steroid creams, such as 1 percent",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?38/9/39056?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    (available in the United States without prescription) are not usually helpful. A stronger prescription formula may be helpful.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Steroids",
"    </span>",
"    &nbsp;&mdash;&nbsp;If you develop severe symptoms or the rash covers a large area (especially on the face or genitals), you may need steroid pills (eg,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?27/36/28230?source=see_link\">",
"     prednisone",
"    </a>",
"    ) or injections (eg,",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?0/13/209?source=see_link\">",
"     triamcinolone",
"    </a>",
"    acetonide) to help relieve itching and swelling. Pills are usually given for 14 to 21 days, with the dosage slowly decreased over time.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Skin infections are a potential complication of poison ivy, especially if you scratch your skin. If you develop a skin infection because of poison ivy dermatitis, you may need antibiotics to treat the infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Other treatments",
"    </span>",
"    &nbsp;&mdash;&nbsp;You should not use antihistamine creams or lotions, anesthetic creams containing",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?26/58/27557?source=see_link\">",
"     benzocaine",
"    </a>",
"    , or antibiotic creams containing",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?35/63/36852?source=see_link\">",
"     neomycin",
"    </a>",
"    or",
"    <a class=\"drug drug_patient\" href=\"UTD.htm?1/56/1925?source=see_link\">",
"     bacitracin",
"    </a>",
"    to the skin. These creams or ointments could make the rash worse.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     POISON IVY PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best way to prevent poison ivy dermatitis is to identify and avoid the plants that cause it. These plants can irritate the skin year round, even during the winter months, and can still cause a reaction after the plant dies.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Wear protective clothing, including long sleeves and pants when working in areas where toxic plants may be found. Keep in mind that the resin and oils from the toxic plants can be carried on clothing, pets, and under fingernails.",
"     </li>",
"     <li>",
"      Wear heavy-duty vinyl gloves when doing yard work or gardening. The oils from toxic plants can seep through latex or rubber gloves.",
"     </li>",
"     <li>",
"      After coming in contact with poison ivy, remove any contaminated clothing and gently wash (do not scrub or rub) your skin and under the fingernails with mild soap and water as soon as possible. Washing within 10 minutes after exposure can reduce the likelihood and severity of symptoms; washing the skin after 10 minutes of exposure typically will not help.",
"     </li>",
"     <li>",
"      Creams and ointments that create a barrier between the skin and the urushiol oil may be somewhat effective for people who are frequently exposed to poison ivy.",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?25/8/25731?source=see_link\">",
"       Bentoquatam",
"      </a>",
"      (Ivy Block&reg;) is one type of barrier cream that may prevent poison ivy dermatitis. It must be reapplied every four hours and it leaves a clay residue on the skin.",
"     </li>",
"     <li>",
"      Avoid burning poisonous vegetation, which can disperse the plant particles in the smoke, irritate the skin, and cause poison ivy dermatitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     WHERE TO GET MORE INFORMATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Your healthcare provider is the best source of information for questions and concerns related to your medical problem.",
"   </p>",
"   <p>",
"    This article will be updated as needed on our web site (",
"    <a class=\"external\" href=\"file://www.uptodate.com/patients\">",
"     www.uptodate.com/patients",
"    </a>",
"    ). Related topics for patients, as well as selected articles written for healthcare professionals, are also available. Some of the most relevant are listed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Patient level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27047769\">",
"    <span class=\"h3\">",
"     The Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Basics patient education pieces answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?3/3/3122?source=see_link\">",
"     Patient information: Poison ivy (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?1/53/1874?source=see_link\">",
"     Patient information: Dermatitis (The Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_basics\" href=\"UTD.htm?4/60/5058?source=see_link\">",
"     Patient information: Blisters (The Basics)",
"    </a>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27047777\">",
"    <span class=\"h3\">",
"     Beyond the Basics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    This topic currently has no corresponding Beyond the Basics content.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27047792\">",
"    <span class=\"h2\">",
"     Professional level information",
"    </span>",
"    &nbsp;&mdash;&nbsp;Professional level articles are designed to keep doctors and other health professionals up-to-date on the latest medical findings. These articles are thorough, long, and complex, and they contain multiple references to the research on which they are based. Professional level articles are best for people who are comfortable with a lot of medical terminology and who want to read the same materials their doctors are reading.",
"   </p>",
"   <p>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26104?source=see_link\">",
"     Contact dermatitis in children",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=see_link\">",
"     Overview of dermatitis",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/44/20168?source=see_link\">",
"     Poison ivy (Toxicodendron) dermatitis",
"    </a>",
"    <br/>",
"    <br/>",
"    The following organizations also provide reliable health information.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Academy of Allergy, Asthma, and Immunology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.aaaai.org/\">",
"     www.aaaai.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      American Academy of Dermatology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.aad.org/\">",
"     www.aad.org",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Institute of Allergy and Infectious Diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"external\" href=\"file://www.niaid.nih.gov/\">",
"     file://www.niaid.nih.gov",
"    </a>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Institute of Arthritis and Musculoskeletal and Skin Diseases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.niams.nih.gov/\">",
"     www.niams.nih.gov",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      National Library of Medicine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;(",
"    <a class=\"external\" href=\"file://www.nlm.nih.gov/medlineplus/healthtopics.html\">",
"     www.nlm.nih.gov/medlineplus/healthtopics.html",
"    </a>",
"    )",
"   </p>",
"   <p>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6068/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6068/abstract/1\">",
"      Crawford GH, McGovern TW. Poison ivy. N Engl J Med 2002; 347:1723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6068/abstract/2\">",
"      Parkinson G. Images in clinical medicine. The many faces of poison ivy. N Engl J Med 2002; 347:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6068/abstract/3\">",
"      Stibich AS, Yagan M, Sharma V, et al. Cost-effective post-exposure prevention of poison ivy dermatitis. Int J Dermatol 2000; 39:515.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7632 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-9843F0D5B8-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6068=[""].join("\n");
var outline_f5_59_6068=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      POISON IVY DERMATITIS CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      IDENTIFYING POISON IVY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      POISON IVY SIGNS AND SYMPTOMS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      POISON IVY DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      POISON IVY TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Skin treatments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Antihistamines",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Steroid creams",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Steroids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Other treatments",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      POISON IVY PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      WHERE TO GET MORE INFORMATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Patient level information",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27047769\">",
"      - The Basics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27047777\">",
"      - Beyond the Basics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27047792\">",
"      Professional level information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/7632\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/7632|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?40/20/41282\" title=\"figure 1\">",
"      Identifying poison ivy PI",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PI/7632|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?0/47/757\" title=\"picture 1A\">",
"      Poison ivy 1 PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/48/26371\" title=\"picture 1B\">",
"      Poison ivy fruit PI",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/0/7176\" title=\"picture 1C\">",
"      Poison oak PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/31/26104?source=related_link\">",
"      Contact dermatitis in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/40/3721?source=related_link\">",
"      Overview of dermatitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?4/60/5058?source=related_link\">",
"      Patient information: Blisters (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/53/1874?source=related_link\">",
"      Patient information: Dermatitis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?3/3/3122?source=related_link\">",
"      Patient information: Poison ivy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/44/20168?source=related_link\">",
"      Poison ivy (Toxicodendron) dermatitis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_59_6069="Leukemia cutis forearms";
var content_f5_59_6069=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F55331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F55331&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Leukemia cutis forearms",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 328px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Leukemia cutis: extensor forearms.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Stedman's Medical Dictionary. Copyright &copy;2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6069=[""].join("\n");
var outline_f5_59_6069=null;
var title_f5_59_6070="Critical pathways in controlling mycobacterial infection";
var content_f5_59_6070=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F50107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F50107&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 523px\">",
"   <div class=\"ttl\">",
"    Critical pathways in controlling mycobacterial infection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 503px; height: 618px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mycobacterial infection induces IL-12 production by monocytes, which stimulates T-cells and NK cells to produce IFN-&gamma;. After binding to its cognate receptor, IFN-&gamma; activates macrophages to produce TNF-&alpha; and to kill mycobacteria intracellularly by mechanisms not yet defined. IFN-&gamma; also drives IL-12 production forward.",
"    <div class=\"footnotes\">",
"     AFB: acid fast bacilli; NO: nitric oxide; IFN-&gamma;R1: interferon g receptor 2; IL-12R&beta;1 and IL-12R&beta;2: interleukin 12 receptor chains; TNF-&alpha;: tumor necrosis factor &alpha;; TNF-&alpha;R: tumor necrosis factor &alpha; receptors.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Gulbu Uzel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6070=[""].join("\n");
var outline_f5_59_6070=null;
var title_f5_59_6071="Bronchial atresia CXR";
var content_f5_59_6071=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F82218%7EPULM%2F63130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F82218%7EPULM%2F63130&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchial atresia in infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 360px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph shows marked hyperexpansion and oligemia of the left upper lobe. A small suprahilar nodule is visible in the left upper lobe.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Bronchial atresia in infant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 392px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A Bronchogram performed with oily Dionosil shows an absent superior division of the left upper lobe bronchus, with the lingular and left lower lobe bronchi displaced caudad.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6071=[""].join("\n");
var outline_f5_59_6071=null;
var title_f5_59_6072="Progesterone: Drug information";
var content_f5_59_6072=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Progesterone: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?34/14/35045?source=see_link\">",
"    see \"Progesterone: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5709349\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F213986\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Crinone&reg;;",
"     </li>",
"     <li>",
"      Endometrin&reg;;",
"     </li>",
"     <li>",
"      First&trade;-Progesterone VGS 100;",
"     </li>",
"     <li>",
"      First&trade;-Progesterone VGS 200;",
"     </li>",
"     <li>",
"      First&trade;-Progesterone VGS 25;",
"     </li>",
"     <li>",
"      First&trade;-Progesterone VGS 400;",
"     </li>",
"     <li>",
"      First&trade;-Progesterone VGS 50;",
"     </li>",
"     <li>",
"      Prometrium&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F213987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Crinone&reg;;",
"     </li>",
"     <li>",
"      Prometrium&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F214026\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Progestin",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F213991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Females:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Amenorrhea:",
"     </b>",
"     I.M.: 5-10 mg/day for 6-8 consecutive days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Amenorrhea, secondary:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intravaginal gel:",
"     </i>",
"     45 mg (4% gel) every other day for 6 doses; if response is inadequate, may increase to 90 mg (8% gel) at same schedule",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Oral:",
"     </i>",
"     400 mg every evening for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ART in patients who require progesterone supplementation:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intravaginal gel:",
"     </i>",
"     90 mg (8% gel) once daily. If pregnancy occurs, may continue treatment for 10-12 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intravaginal tablet:",
"     </i>",
"     100 mg 2-3 times daily starting at oocyte retrieval and continuing for up to 10 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      ART in patients with partial or complete ovarian failure:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <i>",
"      Intravaginal gel:",
"     </i>",
"     90 mg (8% gel) twice daily. If pregnancy occurs, continue treatment for 10-12 weeks.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Endometrial hyperplasia prevention",
"     </b>",
"     (in postmenopausal women with a uterus who are receiving daily conjugated estrogen tablets): Oral: 200 mg as a single daily dose every evening for 12 days sequentially per 28-day cycle",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Functional uterine bleeding:",
"     </b>",
"     I.M.: 5-10 mg/day for 6 doses",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F213992\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F213962\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral [micronized]: 100 mg, 200 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Prometrium&reg;: 100 mg, 200 mg [contains peanut oil]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gel, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Crinone&reg;: 4% (1.45 g) [contains palm oil; 45 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Crinone&reg;: 8% (1.45 g) [contains palm oil; 90 mg/dose]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, oil: 50 mg/mL (10 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Suppository, vaginal [compounding kit]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     First&trade;-Progesterone VGS 25: 25 mg (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     First&trade;-Progesterone VGS 50: 50 mg (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     First&trade;-Progesterone VGS 100: 100 mg (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     First&trade;-Progesterone VGS 200: 200 mg (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     First&trade;-Progesterone VGS 400: 400 mg (30s)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, vaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endometrin&reg;: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F213946\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule, injection",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F213966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Administer deep I.M. only",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intravaginal:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vaginal gel: (A small amount of gel will remain in the applicator following insertion): Administer into the vagina directly from sealed applicator. Remove applicator from wrapper; holding applicator by thickest end, shake down to move contents to thin end; while holding applicator by flat section of thick end, twist off tab; gently insert into vagina and squeeze thick end of applicator.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     For use at altitudes above 2500 feet: Remove applicator from wrapper; hold applicator on both sides of bubble in the thick end; using a lancet, make a single puncture in the bubble to relieve air pressure; holding applicator by thickest end, shake down to move contents to thin end; while holding applicator by flat section of thick end, twist off tab; gently insert into vagina and squeeze thick end of applicator.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Vaginal tablet: Insert tablet in vagina using disposable applicator provided.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral capsule: For patients who experience difficulty swallowing the capsules, taking with a full glass of water in the standing position may be beneficial.",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Hazardous agent; use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F213965\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: Prevention of endometrial hyperplasia in nonhysterectomized, postmenopausal women who are receiving conjugated estrogen tablets; secondary amenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M.: Amenorrhea; abnormal uterine bleeding due to hormonal imbalance",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Intravaginal gel: Part of assisted reproductive technology (ART) for infertile women with progesterone deficiency; secondary amenorrhea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Vaginal tablet: Part of ART for infertile women with progesterone deficiency",
"    </p>",
"   </div>",
"   <div class=\"block usu drugH1Div\" id=\"F15245238\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use - Unlabeled",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Reduce the risk of recurrent spontaneous preterm birth in appropriately selected women",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F214024\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Injection (I.M.):",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Cerebral edema, cerebral thrombosis, edema",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Depression, fever, insomnia, somnolence",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Dermatologic: Acne, allergic rash (rare), alopecia, hirsutism, pruritus, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Amenorrhea, breakthrough bleeding, breast tenderness, galactorrhea, menstrual flow changes, spotting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Cervical erosion changes, cervical secretion changes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hepatic: Cholestatic jaundice",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Local: Injection site: Irritation, pain, redness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ocular: Optic neuritis, retinal thrombosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Pulmonary embolism",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Anaphylactoid reactions",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Oral capsule",
"     </b>",
"     (percentages reported when used in combination with or cycled with conjugated estrogens):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (16% to 31%), dizziness (15% to 24%), depression (19%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast tenderness (27%), breast pain (6% to 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (10% to 20%), abdominal bloating (8% to 12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Urinary problems (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Joint pain (20%), musculoskeletal pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Miscellaneous: Viral infection (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cardiovascular: Chest pain (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Fatigue (8%), irritability (8%), worry (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea/vomiting (8%), diarrhea (7% to 8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal discharge (10%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Respiratory: Cough (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;5%: Breast biopsy, breast cancer, cholecystectomy, constipation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Postmarketing and/or case reports: Aggression, alopecia, anaphylactic reaction, arthralgia, asthma, blurred vision, choking, cholestasis, cholestatic hepatitis, circulatory collapse, confusion, consciousness depressed/loss, convulsion, depersonalization, diplopia, disorientation, drunk feeling, dysarthria, dysphagia, dyspnea, endometrial carcinoma, facial edema, feeling abnormal, gait abnormal, hepatic enzymes increased, hepatic failure, hepatic necrosis, hepatitis, hyperglycemia, hyper-/hypotension, hypersensitivity, jaundice, liver function tests increased, menorrhagia, menstrual disorder, metrorrhagia, muscle cramps, ovarian cyst, pancreatitis (acute), paresthesia, pruritus, sedation, slurred speech, stupor, suicidal ideation, syncope, tachycardia, throat tightness, TIA, tinnitus, tongue swelling, urticaria, vertigo, visual disturbance, walking difficulty, weight gain/loss",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Vaginal gel",
"     </b>",
"     (percentages reported with ART); also refer to oral capsule reactions listing for additional effects noted with progesterone:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Somnolence (27%), headache (13% to 17%), nervousness (16%), depression (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Breast enlargement (40%), breast pain (13%), libido decreased (11%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Constipation (27%), nausea (7% to 22%), cramps (15%), abdominal pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Perineal pain (17%), nocturia (13%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     5% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Pain (8%), dizziness (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Diarrhea (8%), bloating (7%), vomiting (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal discharge (7%), dyspareunia (6%), genital moniliasis (5%), genital pruritus (5%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Arthralgia (8%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Vaginal tablet",
"     </b>",
"     (percentages reported with ART); also refer to oral capsule reactions listing for additional effects noted with progesterone:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &gt;10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain (12%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Miscellaneous: Post-oocyte retrieval pain (25% to 28%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Central nervous system: Headache (3% to 4%), fatigue (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Ovarian hyperstimulation syndrome (7%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Gastrointestinal: Nausea (7% to 8%), abdominal distension (4%), constipation (2% to 3%), vomiting (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;margin-top:0em;text-align:justify;\">",
"     Genitourinary: Uterine spasm (3% to 4%), vaginal bleeding (3%), urinary tract infection (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;text-align:justify;\">",
"     &lt;1%: Burning, discomfort, itching, peripheral edema, urticaria, vaginal irritation",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F213969\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to progesterone or any component of the formulation; undiagnosed abnormal vaginal bleeding; history of or current thrombophlebitis or venous thromboembolic disorders (including DVT, PE); active or history of arterial thromboembolic disease (eg, stroke, MI); history of or known or suspected carcinoma of the breast or genital organs; hepatic dysfunction or disease; missed abortion or ectopic pregnancy; diagnostic test for pregnancy; capsules are also contraindicated for use during pregnancy",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F213950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Breast cancer:",
"     <b>",
"      [U.S. Boxed Warning]: Based on data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of invasive breast cancer was observed in postmenopausal women using conjugated estrogens (CE) in combination with medroxyprogesterone acetate (MPA).",
"     </b>",
"     This risk may be associated with duration of use and declines once combined therapy is discontinued (Chlebowski, 2009). The risk of invasive breast cancer was decreased in postmenopausal women with a hysterectomy using CE only, regardless of weight. However, the risk was not significantly decreased in women at high risk for breast cancer (family history of breast cancer, personal history of benign breast disease) (Anderson, 2012). An increase in abnormal mammogram findings has also been reported with estrogen alone or in combination with progestin therapy. Use is contraindicated in patients with known or suspected breast cancer.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Patients should be warned that progesterone might cause transient dizziness or drowsiness during initial therapy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dementia:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent dementia. In the Women&rsquo;s Health Initiative Memory Study (WHIMS), an increased incidence of dementia was observed in women &ge;65 years of age taking CE alone or in combination with MPA .",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Endometrial carcinoma: Progesterone is used to reduce the risk of endometrial hyperplasia in nonhysterectomized postmenopausal women receiving conjugated estrogens. The use of unopposed estrogen in women with an intact uterus is associated with an increased risk of endometrial cancer. The addition of a progestin to estrogen therapy may decrease the risk of endometrial hyperplasia, a precursor to endometrial cancer. Adequate diagnostic measures, including endometrial sampling if indicated, should be performed to rule out malignancy in postmenopausal women with undiagnosed abnormal vaginal bleeding. Estrogens may exacerbate endometriosis. Malignant transformation of residual endometrial implants has been reported posthysterectomy with unopposed estrogen therapy. Consider adding a progestin in women with residual endometriosis posthysterectomy.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Ovarian cancer: Postmenopausal estrogen therapy and combined estrogen/progesterone therapy may increase the risk of ovarian cancer; however, the absolute risk to an individual woman is small. Although results from various studies are not consistent, risk does not appear to be significantly associated with the duration, route, or dose of therapy. In one study, the risk decreased after 2 years following discontinuation of therapy (M&oslash;rch, 2009). Although the risk of ovarian cancer is rare, women who are at an increased risk (eg, family history) should be counseled about the association (NAMS, 2012).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Retinal vascular thrombosis: Discontinue pending examination in cases of sudden partial or complete vision loss, sudden onset of proptosis, diplopia, or migraine; discontinue permanently if papilledema or retinal vascular lesions are observed on examination.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should not be used to prevent cardiovascular disease.",
"     </b>",
"     Using data from the Women&rsquo;s Health Initiative (WHI) studies, an increased risk of deep vein thrombosis (DVT) and stroke has been reported with CE and an increased risk of DVT, stroke, pulmonary emboli (PE) and myocardial infarction (MI) has been reported with CE with MPA in postmenopausal women. Additional risk factors include diabetes mellitus, hypercholesterolemia, hypertension, SLE, obesity, tobacco use, and/or history of venous thromboembolism (VTE). Risk factors should be managed appropriately; discontinue use if adverse cardiovascular events occur or are suspected.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Depression: Use with caution in patients with a history of depression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diseases exacerbated by fluid retention: Use with caution in patients with diseases which may be exacerbated by fluid retention, including asthma, epilepsy, migraine, diabetes, or renal dysfunction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Not for use prior to menarche.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Surgical patients: Whenever possible, progestins in combination with estrogens should be discontinued at least 4-6 weeks prior to and for 2 weeks following elective surgery associated with an increased risk of thromboembolism or during periods of prolonged immobilization.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Benzyl alcohol: Some products may contain benzyl alcohol.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Palm oil: Some products may contain palm oil.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Peanut oil: Some products may contain peanut oil.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sesame oil: Some products may contain sesame oil.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special handling:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hazardous agent: Use appropriate precautions for handling and disposal",
"     <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"      (NIOSH, 2012)",
"     </a>",
"     .",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Risks vs benefits:",
"     <b>",
"      [U.S. Boxed Warning]: Estrogens with or without progestin should be used for the shortest duration possible at the lowest effective dose consistent with treatment goals.",
"     </b>",
"     Before prescribing estrogen therapy to postmenopausal women, the risks and benefits must be weighed for each patient. Women should be informed of these risks and benefits, as well as possible effects of progestin when added to estrogen therapy. Patients should be reevaluated as clinically appropriate to determine if treatment is still necessary. Available data related to treatment risks are from Women&rsquo;s Health Initiative (WHI) studies, which evaluated oral CE 0.625 mg with or without MPA 2.5 mg relative to placebo in postmenopausal women. Other combinations and dosage forms of estrogens and progestins were not studied.",
"     <b>",
"      Outcomes reported from clinical trials using CE with or without MPA should be assumed to be similar for other doses and other dosage forms of estrogens and progestins until comparable data becomes available.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F214021\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2A6 (minor), CYP2C19 (major), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP2C19 (weak), CYP2C9 (weak), CYP3A4 (weak), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F213955\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aminoglutethimide: May increase the metabolism of Progestins. Management: Progestin-containing contraceptives are not recommended; consider the use of alternative, nonhormonal contraceptives.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Colchicine. Colchicine distribution into certain tissues (e.g., brain) may also be increased.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a p-glycoprotein inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP2C19 Inducers (Strong): May increase the metabolism of CYP2C19 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May increase the metabolism of CYP3A4 Substrates. Management: Consider an alternative for one of the interacting drugs. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Everolimus.  Management: Everolimus dose reductions are required for patients being treated for subependymal giant cell astrocytoma or renal cell carcinoma.  See prescribing information for specific dose adjustment and monitoring recommendations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (Progestogenic Properties) (eg, Bloodroot, Yucca): May enhance the adverse/toxic effect of Progestins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F213981\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Food: Food increases oral bioavailability.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: St John's wort may decrease progesterone levels. Herbs with progestogenic properties may enhance the adverse/toxic effects of progestin; example herbs include bloodroot, chasteberry, damiana, oregano, yucca.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F213958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (Prometrium&reg;; none established for vaginal gel, vaginal tablet, or injection (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F213972\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events were not observed following oral administration in animal reproduction studies. There is an increased risk of minor birth defects in children whose mothers take progesterones during the first 4 months of pregnancy. Hypospadias has been reported in male and mild masculinization of the external genitalia has been reported in female babies exposed during the first trimester. Cleft lip, cleft palate, congenital heart disease, patent ductus arteriosus, ventricular septal defect, intrauterine death, and spontaneous abortion have been noted in case reports following use of oral progesterone during pregnancy. High doses of progesterone would be expected to impair fertility. Use of vaginal progesterone may be considered to decrease the risk of recurrent spontaneous preterm birth in women with a singleton pregnancy and prior spontaneous preterm singleton birth; use is not recommended as an intervention for women with multiple gestations (ACOG, 2012). The vaginal gel and tablet are indicated for use in ART. The oral capsules are contraindicated for use during pregnancy.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F213994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution (AAP rates &ldquo;compatible&rdquo;; AAP 2001 update pending)",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F213971\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Progesterone Micronized Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $213.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $404.96",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Prometrium Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $278.28",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (100): $528.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Gel",
"     </b>",
"     (Crinone Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     4% (1.45 g): $11.72",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     8% (1.45 g): $19.53",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      INST",
"     </b>",
"     (Endometrin Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (21): $201.61",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Oil",
"     </b>",
"     (Progesterone Intramuscular)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg/mL (10 mL): $35.88",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (First-Progesterone VGS 100 Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (30): $112.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (First-Progesterone VGS 200 Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (30): $118.40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (First-Progesterone VGS 25 Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (30): $107.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (First-Progesterone VGS 400 Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (30): $127.00",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Suppository",
"     </b>",
"     (First-Progesterone VGS 50 Vaginal)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50 mg (30): $110.00",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F213960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Routine physical examination that includes blood pressure and Papanicolaou smear, breast exam, mammogram. Adequate diagnostic measures, including endometrial sampling, if indicated, should be performed to rule out malignancy in all cases of undiagnosed abnormal vaginal bleeding. Signs and symptoms of thromboembolic disorders, vision changes",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F213973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Crinone (AR, AU, BE, CH, CL, DE, DK, ES, FI, GB, GR, HK, ID, IE, IL, IT, KP, MY, NO, NZ, PH, RU, SE, SG, TR, TW, UY, VE);",
"     </li>",
"     <li>",
"      Cyclogest (AE, BH, CY, EG, IQ, IR, JO, KW, LB, LY, MY, OM, PK, QA, SA, SG, SY, YE, ZA);",
"     </li>",
"     <li>",
"      Cygest (ID);",
"     </li>",
"     <li>",
"      Endometrin (HK, IL);",
"     </li>",
"     <li>",
"      Estima Ge (FR);",
"     </li>",
"     <li>",
"      Gepromi (MX);",
"     </li>",
"     <li>",
"      Geslutin (CO, DO, GT, HN, MX, NI);",
"     </li>",
"     <li>",
"      Geslutin PNM (EC, PE);",
"     </li>",
"     <li>",
"      Glanducorpin (HU);",
"     </li>",
"     <li>",
"      Gynprogest (PY);",
"     </li>",
"     <li>",
"      Luteina (PL);",
"     </li>",
"     <li>",
"      Mafel (AR);",
"     </li>",
"     <li>",
"      Naturogest (IN);",
"     </li>",
"     <li>",
"      Progendo (CN);",
"     </li>",
"     <li>",
"      Progering (PE);",
"     </li>",
"     <li>",
"      Progestan (NL);",
"     </li>",
"     <li>",
"      Progestin (PA, SV);",
"     </li>",
"     <li>",
"      Progestogel (HK, LU);",
"     </li>",
"     <li>",
"      Utrogestan (AT, BE, BG, BR, CH, CZ, EC, ES, FR, GB, HU, KP, LU, MX, MY, PH, PT, SG, UY)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F213949\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Natural steroid hormone that induces secretory changes in the endometrium, promotes mammary gland development, relaxes uterine smooth muscle, blocks follicular maturation and ovulation, and maintains pregnancy. When used as part of an ART program in the luteal phase, progesterone supports embryo implantation.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F213968\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Vaginal gel: Prolonged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Absorption half-life: 25-50 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: Albumin (50% to 54%) and cortisol-binding protein (43% to 48%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Hepatic to metabolites",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Vaginal gel: 5-20 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: Oral: Within 3 hours; I.M.: ~8 hours; Vaginal tablet: ~17-24 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine, bile, feces",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Academy of Pediatrics Committee on Drugs, \"Transfer of Drugs and Other Chemicals Into Human Milk,\"",
"      <i>",
"       Pediatrics",
"      </i>",
"      , 2001, 108(3):776-89.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6072/abstract-text/11533352/pubmed\" id=\"11533352\" target=\"_blank\">",
"        11533352",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists (ACOG), Practice Bulletin No. 130, \"Prediction and Prevention of Preterm Birth,\"",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2012, 120(4):964-73.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6072/abstract-text/22996126/pubmed\" id=\"22996126\" target=\"_blank\">",
"        22996126",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Chlebowski RT, Aragaki AK, et al, \"Conjugated Equine Oestrogen and Breast Cancer Incidence and Mortality in Postmenopausal Women With Hysterectomy: Extended Follow-Up of the Women's Health Initiative Randomised Placebo-Controlled Trial,\"",
"      <i>",
"       Lancet Oncol,",
"      </i>",
"      2012, 13(5):476-86.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6072/abstract-text/22401913/pubmed\" id=\"22401913\" target=\"_blank\">",
"        22401913",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Anderson GL, Limacher M, Assaf AR, et al, \"Effects of Conjugated Equine Estrogen In Postmenopausal Women With Hysterectomy: The Women's Health Initiative Randomized Controlled Trial.\"",
"      <i>",
"       JAMA",
"      </i>",
"      , 2004, 291(14):1701-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6072/abstract-text/15082697/pubmed\" id=\"15082697\" target=\"_blank\">",
"        15082697",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chlebowski RT, Kuller LH, Prentice RL, et al, \"Breast Cancer After Use of Estrogen Plus Progestin in Postmenopausal Women,\"",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 2009, 360(6):573-87.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6072/abstract-text/19196674/pubmed\" id=\"19196674\" target=\"_blank\">",
"        19196674",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Doody K, Shamma N, Paulson R, et al. &ldquo;Endometrin&reg; for Luteal Phase Support in a Randomized, Controlled, Open-Label, Prospective IVF Clinical Trial Using a Combination of Menopur&reg; and Bravelle&reg;,&rdquo;",
"      <i>",
"       Fertil Steril",
"      </i>",
"      , 2007, 87(4 Suppl 2):24.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6072/abstract-text/17081533/pubmed\" id=\"17081533\" target=\"_blank\">",
"        17081533",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hsia J, Langer RD, Manson JE, et al, \"Conjugated Equine Estrogens and Coronary Heart Disease: The Women's Health Initiative,\"",
"      <i>",
"       Arch Intern Med",
"      </i>",
"      , 2006, 166(3):357-65.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6072/abstract-text/16476878/pubmed\" id=\"16476878\" target=\"_blank\">",
"        16476878",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      M&oslash;rch LS, L&oslash;kkegaard E, Andreasen AH, et al, &ldquo;Hormone Therapy and Ovarian Cancer,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2009, 302(3):298-305.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6072/abstract-text/19602689/pubmed\" id=\"19602689\" target=\"_blank\">",
"        19602689",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Institute for Occupational Safety and Health (NIOSH), \"NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings 2012.\" Available at",
"      <a href=\"file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf\" target=\"_blank\">",
"       file://www.cdc.gov/niosh/docs/2012-150/pdfs/2012-150.pdf",
"      </a>",
"      . Accessed January 21, 2013.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Ng EH, Chan CC, Tang OS, et al,  &ldquo;A Randomized Comparison of Side Effects and Patient Convenience Between Cyclogest&reg; Suppositories and Endometrin&reg; Tablets Used for Luteal Phase Support in IVF Treatment,&rdquo;",
"      <i>",
"       Eur J Obstet Gynecol Reprod Biol",
"      </i>",
"      , 2007, 131(2):182-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6072/abstract-text/16920249/pubmed\" id=\"16920249\" target=\"_blank\">",
"        16920249",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      North American Menopause Society [NAMS], \"The 2012 Hormone Therapy Position Statement of The North American Menopause Society,\"",
"      <i>",
"       Menopause",
"      </i>",
"      , 2012, 19(3):257-71.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6072/abstract-text/22367731/pubmed\" id=\"22367731\" target=\"_blank\">",
"        22367731",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rossouw JE, Anderson GL, Prentice RL, et al, &ldquo;Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principle Results From the Women's Health Initiative Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2002, 288(3):321-33.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6072/abstract-text/12117397/pubmed\" id=\"12117397\" target=\"_blank\">",
"        12117397",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Shumaker SA, Legault C, Rapp SR, et al, &ldquo;Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal Women: The Women's Health Initiative Memory Study: A Randomized Controlled Trial,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 2003, 289(20):2651-62.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6072/abstract-text/12771112/pubmed\" id=\"12771112\" target=\"_blank\">",
"        12771112",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9817 Version 43.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-BD1901CB76-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6072=[""].join("\n");
var outline_f5_59_6072=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5709349\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213986\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213987\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214026\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213991\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213992\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213962\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213946\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213966\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213965\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15245238\">",
"      Use - Unlabeled",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214024\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213969\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213950\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F214021\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213955\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213981\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213958\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213972\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213994\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213971\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213960\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213973\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213949\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F213968\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9817\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9817|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?34/14/35045?source=related_link\">",
"      Progesterone: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_59_6073="Prevention of cytomegalovirus infection in lung transplant recipients";
var content_f5_59_6073=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention of cytomegalovirus infection in lung transplant recipients",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/59/6073/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/59/6073/contributors\">",
"     Martin Zamora, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/59/6073/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/59/6073/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/59/6073/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?5/59/6073/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?5/59/6073/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?5/59/6073/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1635497404\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cytomegalovirus (CMV), a member of the betaherpesvirus group, remains an important cause of morbidity and mortality in lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/1\">",
"     1",
"    </a>",
"    ]. It is the second most common infection among lung transplant recipients, after bacterial pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While the development and availability of potent antiviral agents has decreased CMV-related mortality, there is a growing body of evidence that the indirect effects of CMV may be equally important or even more important than its direct effects of tissue injury and infection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/3\">",
"     3",
"    </a>",
"    ]. CMV-induced immunosuppression may lead to infection with other opportunistic organisms. In addition, CMV infection and disease have been associated with acute and chronic rejection (bronchiolitis obliterans syndrome) in some, but not all studies [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/4-6\">",
"     4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach to prevention of CMV infections in lung transplant recipients continues to evolve as transplant specialists gain experience using molecular diagnostic techniques and the potent oral antiviral agent,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    . The prevention of CMV infection in lung transplant recipients will be discussed here. The clinical manifestations, diagnosis, and treatment of CMV infection in lung transplant recipients, and infectious complications due to agents other than CMV are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link\">",
"     \"Bacterial infections following lung transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=see_link\">",
"     \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=see_link\">",
"     \"Tuberculosis in solid organ transplant candidates and recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link\">",
"     \"Fungal infections following lung transplantation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1635497410\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary CMV infection is acquired through close physical contact involving direct inoculation with infected cells or body fluids. Following primary infection, CMV infection persists for life. Population studies document a gradual increase in CMV seropositivity through young adulthood. Although there is considerable variability, more than one-half of adults in the United States have serologic evidence of previous infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13722?source=see_link\">",
"     \"Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent hosts\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CMV infection following transplantation can be acquired in one of several ways [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/3\">",
"     3",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      By transmission with the donor organ from a CMV-seropositive donor",
"     </li>",
"     <li>",
"      By transfusion of blood products from a CMV-seropositive blood donor",
"     </li>",
"     <li>",
"      By reactivation of latent infection in a seropositive recipient",
"     </li>",
"     <li>",
"      By close physical contact with a CMV-infected individual",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H572193\">",
"    <span class=\"h1\">",
"     GUIDELINES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Guidelines for the management of CMV in solid organ transplantation were published by the American Society of Transplantation in 2009 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/7\">",
"     7",
"    </a>",
"    ], and by the Transplantation Society International CMV Consensus Group in 2010 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8\">",
"     8",
"    </a>",
"    ]. In addition, recommendations for the management of CMV infection in lung transplant recipients were published in 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/9\">",
"     9",
"    </a>",
"    ]. The following discussion and recommendations are generally in accordance with these documents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H572056\">",
"    <span class=\"h1\">",
"     INFECTION VERSUS DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV infection and disease are not synonymous terms; not all patients with infection develop overt clinical disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      CMV infection is defined as evidence of CMV replication regardless of symptoms [",
"      <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/7,10\">",
"       7,10",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H1635497428\">",
"       'Diagnostic tests'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      CMV disease is defined as evidence of CMV infection with attributable symptoms and signs; CMV disease may manifest as either a viral syndrome with fever, malaise, leukopenia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia, or as tissue invasive disease [",
"      <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/7,10\">",
"       7,10",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link&amp;anchor=H709584835#H709584835\">",
"       \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\", section on 'Clinical features'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H75824932\">",
"    <span class=\"h1\">",
"     RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most important risk factor for CMV infection and disease in lung transplant recipients is CMV serologic status, with seronegative recipients of seropositive organs (CMV",
"    <span class=\"nowrap\">",
"     D+/R-)",
"    </span>",
"    having the highest risk. Immunosuppressive regimens can also play a major role on the impact of CMV replication in lung transplant recipients. In particular, the use of anti-lymphocyte antibodies as induction therapy or for the treatment of steroid-resistant rejection has been strongly associated with the development of CMV disease in seropositive recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. High doses of glucocorticoids have also been identified as a risk factor for CMV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1635497416\">",
"    <span class=\"h2\">",
"     Serologic status",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall likelihood of developing CMV infection or disease in lung transplant recipients ranges from 54 to 92 percent in patients without prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/9,14,15\">",
"     9,14,15",
"    </a>",
"    ]. The most important risk factor for CMV infection and disease is organ donor (D) and recipient (R) serostatus, with CMV",
"    <span class=\"nowrap\">",
"     D+/R-",
"    </span>",
"    recipients at the highest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/9,14\">",
"     9,14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H572572\">",
"     'Universal prophylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The lung has been identified as a major site of CMV latency and recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/16\">",
"     16",
"    </a>",
"    ]. Lung transplantation is associated with the transfer of a larger CMV viral load than other solid organs and, as a result, the risk of CMV infection and disease is greater than in other solid organ transplant recipients. Therefore, most lung transplant programs employ aggressive preventive measures for all D+ or R+ lung transplant recipients.",
"   </p>",
"   <p>",
"    Serologic status impacts the risk of CMV infection as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        D+/R-:",
"       </strong>",
"      </span>",
"      CMV",
"      <span class=\"nowrap\">",
"       D+/R-",
"       <strong>",
"       </strong>",
"      </span>",
"      recipients are at the greatest risk CMV, with infection occurring in up to 71 percent of recipients with 85 percent of infected individuals developing disease. The case-fatality rate of patients with CMV disease has approached 22 percent but due to the availability of potent antiviral agents, mortality has been substantially reduced [",
"      <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/3\">",
"       3",
"      </a>",
"      ]. In a single-center series, the survival rate for CMV-mismatched recipients was similar to that for other donor-recipient serologic combinations [",
"      <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/17\">",
"       17",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        D-/R+",
"       </strong>",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       D+/R+:",
"      </span>",
"      Infection develops in approximately 58 and 69 percent of CMV",
"      <span class=\"nowrap\">",
"       D-/R+",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       D+/R+",
"      </span>",
"      recipients, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/18\">",
"       18",
"      </a>",
"      ]. The risk is higher in the latter group because reactivation as well as superinfection with a new virus strain can occur. Progression from CMV infection to disease is less common in these recipients who have immunity to CMV, occurring in one-fourth to one-third of cases.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       <strong>",
"        D-/R-:",
"       </strong>",
"      </span>",
"      The risk of CMV infection is lowest in seronegative recipients of seronegative donor lungs (CMV",
"      <span class=\"nowrap\">",
"       D-/R-).",
"      </span>",
"      When blood products from CMV-negative blood donors are used exclusively, the rate of CMV infection was decreased from 22 to 8 percent [",
"      <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/19\">",
"       19",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1635497428\">",
"    <span class=\"h1\">",
"     DIAGNOSTIC TESTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic testing to assess the risk of CMV infection prior to transplantation, as well as the use of appropriate diagnostic tests for the detection of active CMV infection following transplantation, are essential for the management of lung transplant recipients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5471661\">",
"    <span class=\"h2\">",
"     Pre-transplant serologic testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;The recipient should be tested for CMV antibodies prior to transplantation, and the donor should be tested before or at the time of transplantation in order to ascertain the need for postoperative prophylaxis. Only CMV IgG should be tested, rather than IgM or a combination of IgM and IgG, since false positive IgM results might reduce the specificity of screening [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8,20-22\">",
"     8,20-22",
"    </a>",
"    ]. Serology should",
"    <strong>",
"     not",
"    </strong>",
"    be used to diagnose active CMV infection or disease in lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H695482\">",
"    <span class=\"h2\">",
"     CMV replication assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Suitable assays for detecting CMV replication should be used to identify patients at risk for developing CMV disease so that treatment can be initiated before invasive disease develops. The available assays have improved considerably in recent years, but continue to have important limitations. Tests for CMV replication include CMV viral load assays and CMV pp65 antigenemia. The choice of test to detect CMV replication in the peripheral blood varies by transplant center. Both viral load testing (using PCR or the hybrid capture assay) and antigenemia testing are acceptable methods, although PCR is used more commonly. We favor using a whole blood, quantitative PCR-based assay. Once a specific assay and type of specimen have been used in a given patient, the same methods should be used for subsequent monitoring, given the lack of standardization of various assays and differences in results based on specimen type.",
"   </p>",
"   <p>",
"    These tests are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link&amp;anchor=H695016#H695016\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\", section on 'CMV replication assays'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=see_link\">",
"     \"Viral load testing for cytomegalovirus in solid organ transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=see_link\">",
"     \"Diagnosis of cytomegalovirus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is not necessary to test for CMV replication in asymptomatic patients receiving appropriate CMV prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8\">",
"     8",
"    </a>",
"    ]. In contrast, patients who are CMV-seropositive or who received an organ from a CMV-seropositive donor who are being managed with a preemptive approach must undergo frequent monitoring for CMV infection. In such patients, monitoring should be done weekly during the first three months following transplantation and during episodes of acute rejection, the periods of highest risk for viral replication [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8\">",
"     8",
"    </a>",
"    ]. In patients who do not have evidence of CMV replication, the frequency of monitoring can be reduced to every two weeks from three until six months post-transplant, and monthly thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/9\">",
"     9",
"    </a>",
"    ]. Results of this monitoring should be used to guide therapy. (See",
"    <a class=\"local\" href=\"#H1635497496\">",
"     'Preemptive therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1635497466\">",
"    <span class=\"h1\">",
"     PREVENTION OF DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because CMV causes considerable morbidity and mortality, and has been identified as a risk factor for chronic rejection in lung transplant recipients, there has been intense interest in prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8,9,18,23\">",
"     8,9,18,23",
"    </a>",
"    ]. Two strategies have been used:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Universal prophylaxis of recipients at high risk for infection (ie, all but CMV donor-negative, recipient-negative [CMV",
"      <span class=\"nowrap\">",
"       D-/R-]",
"      </span>",
"      recipients). This approach most commonly involves antiviral prophylaxis with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Preemptive treatment of recipients with infection in order to abort the development of disease. Using this approach, patients are monitored frequently with a CMV viral load or antigenemia assay, and oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      is initiated when viral replication has reached a certain assay threshold defined at each institution.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Support for the use of universal prophylaxis is based on a substantial body of published evidence in lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. There is a paucity of evidence on the safety and efficacy of preemptive therapy compared with that of universal prophylaxis in lung transplant recipients. Furthermore, few studies have directly compared universal prophylaxis to preemptive therapy in this population.",
"   </p>",
"   <p>",
"    Given the high risk of CMV disease in lung transplant recipients, we favor antiviral prophylaxis over preemptive therapy in all lung transplant recipients who are CMV-seropositive or who received an organ from a CMV-seropositive donor (CMV",
"    <span class=\"nowrap\">",
"     D+/R+,",
"    </span>",
"    <span class=\"nowrap\">",
"     D-/R+,",
"    </span>",
"    <span class=\"nowrap\">",
"     D+/R-)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/9\">",
"     9",
"    </a>",
"    ]. The use of antiviral prophylaxis in seropositive lung transplant recipients is also endorsed by the 2010 International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ Transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8\">",
"     8",
"    </a>",
"    ], and by the 2009 guidelines for the management of CMV in solid organ transplantation published by the American Society of Transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H572572\">",
"    <span class=\"h2\">",
"     Universal prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antiviral prophylaxis (either alone or in combination with CMV immune globulin) is the most widely used prophylactic approach. Oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    and intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    are the drugs of choice for CMV prophylaxis.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/7/31856?source=see_link\">",
"     Acyclovir",
"    </a>",
"    is ineffective for the prevention of CMV infection after lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/19,24,25\">",
"     19,24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2592775\">",
"    <span class=\"h3\">",
"     Ganciclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;A three month course of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    has been shown to reduce the occurrence of CMV illness in all donor-recipient serologic combinations at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. In contrast, a short course of low-dose intravenous ganciclovir during the first three postoperative weeks failed to prevent CMV illness in a small group of recipient-negative, donor-positive lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/28\">",
"     28",
"    </a>",
"    ]. Ganciclovir inhibits viral replication but does not eradicate latent infection. Thus, ganciclovir prophylaxis is effective while it is being administered but does not confer long-term protection [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. However, the delay in onset of CMV infection that it produces is advantageous, because the disease is less frequent and less difficult to manage when the recipient has recuperated from surgery, the effects of cytolytic induction have waned, maintenance immunosuppression is less intense, and the highest-risk period for acute rejection has passed. Nevertheless, there is still a substantial rate of CMV infection and disease in individuals who receive only three months of antiviral prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/29\">",
"     29",
"    </a>",
"    ]. A 12 month course of antiviral prophylaxis with oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    has been shown to be superior to a three month course, as discussed below. (See",
"    <a class=\"local\" href=\"#H2592782\">",
"     'Valganciclovir'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Experience with prophylactic oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    is limited because oral bioavailability is very low. Some benefit has been suggested in CMV mismatched recipients when used after an initial period of intravenous ganciclovir [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/30\">",
"     30",
"    </a>",
"    ]. However, the use of oral ganciclovir has been supplanted by oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    , as discussed in the following section.",
"   </p>",
"   <p>",
"    When intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    is used for prophylaxis, it should be dosed at 5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily, with dose adjustment for renal insufficiency.",
"   </p>",
"   <p>",
"    Hematologic suppression, in particular neutropenia, appears to be the most significant and common adverse event associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    . It is important to note, however, that CMV itself can also cause leukopenia and thrombocytopenia, and that these abnormalities often improve with ganciclovir. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=see_link\">",
"     \"Ganciclovir and valganciclovir: An overview\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link&amp;anchor=H709584835#H709584835\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\", section on 'Clinical features'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2592782\">",
"    <span class=\"h3\">",
"     Valganciclovir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    , a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    prodrug with excellent oral bioavailability, is rapidly becoming the drug of choice for the prophylactic management of CMV infection after lung transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/9,31\">",
"     9,31",
"    </a>",
"    ]. It has proven efficacy in heart, kidney, and kidney-pancreas transplantation compared to oral ganciclovir [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/32\">",
"     32",
"    </a>",
"    ]. One randomized trial and several non-randomized studies have also shown that valganciclovir is effective for the prevention of CMV infection and disease in lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/29,31,33,34\">",
"     29,31,33,34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    The randomized trial included 136 lung transplant recipients with positive donor or recipient CMV serology who received oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    (900 mg orally once daily, with dose adjustment for renal insufficiency) for three months, followed by an additional nine months of either valganciclovir or placebo, the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/29\">",
"     29",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Those who received 12 months of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      prophylaxis were less likely to develop CMV disease than those who received 3 months of valganciclovir prophylaxis (4 versus 32 percent).",
"     </li>",
"     <li>",
"      Individuals who received 12 months of prophylaxis were also less likely to develop CMV infection (10 versus 64 percent) and less likely to have invasive disease (2 versus 21 percent).",
"     </li>",
"     <li>",
"      There were no significant differences between the groups in the incidence of non-CMV opportunistic infections or acute rejection episodes following randomization. &nbsp;",
"     </li>",
"     <li>",
"      There was no difference in the incidence of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      -resistant CMV infection, and there was a similar incidence of CMV disease during the six months following study completion between those who received 12 months of prophylaxis and those who received 3 months of prophylaxis (3 versus 2 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In a subset analysis that included 38 patients who were followed for a mean of 3.9 years, those who received 12 months of prophylaxis continued to have a reduced risk of CMV viremia or pneumonitis compared with those who received 3 months of prophylaxis (12 versus 55 percent; hazard ratio 0.13, 95% CI 0.03-0.61) [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/35\">",
"     35",
"    </a>",
"    ]. White blood cell, neutrophil, and platelet counts were similar between the two groups, demonstrating that the longer duration of prophylaxis did not increase the risk of hematologic toxicity.",
"   </p>",
"   <p>",
"    Based on these results, many experts favor continuing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    prophylaxis for 12 months following lung transplantation in all patients who are CMV-seropositive or who received an organ from a CMV-seropositive donor (CMV",
"    <span class=\"nowrap\">",
"     D+/R+,",
"    </span>",
"    <span class=\"nowrap\">",
"     D-/R+,",
"    </span>",
"    <span class=\"nowrap\">",
"     D+/R-).",
"    </span>",
"    However, some experts prefer to give prophylaxis for six months followed by a preemptive approach with frequent CMV viral load monitoring. When used for prophylaxis, valganciclovir should be dosed at 900 mg orally once daily, with dose adjustment for renal insufficiency. It is important to give appropriate doses of valganciclovir and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    , since inadequate dosing may reduce efficacy and lead to resistance, whereas supratherapeutic dosing may lead to toxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8,36,37\">",
"     8,36,37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The toxicity profile of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    is similar to that of its parent compound,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    . As discussed above, hematologic suppression, in particular neutropenia, appears to be the most significant and common adverse event associated with these agents. (See",
"    <a class=\"local\" href=\"#H2592775\">",
"     'Ganciclovir'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46530082\">",
"    <span class=\"h3\">",
"     CMV immune globulin",
"    </span>",
"    &nbsp;&mdash;&nbsp;At some transplant centers, prophylaxis with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24901?source=see_link\">",
"     cytomegalovirus immune globulin",
"    </a>",
"    (CytoGam) is used in combination with an antiviral agent for prophylaxis of high-risk (eg, CMV",
"    <span class=\"nowrap\">",
"     D+/R-)",
"    </span>",
"    lung transplant recipients [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/31\">",
"     31",
"    </a>",
"    ]; it has been approved by the United Stated Food and Drug Administration in such patients when given in conjunction with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    . A retrospective study compared prophylaxis with ganciclovir plus CMV immune globulin in a group of lung and heart-lung recipients to prophylaxis with ganciclovir alone in a group of historical controls at the same center [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/38\">",
"     38",
"    </a>",
"    ]. In this analysis, freedom from CMV disease, freedom from bronchiolitis obliterans syndrome (chronic rejection), and survival were greater in the first three years after transplantation in the group that received the combination of CMV immune globulin and ganciclovir. Adequately powered, randomized trials measuring the additive benefit of CMV immune globulin in the lung transplant population have not yet been performed.",
"   </p>",
"   <p>",
"    CMV immune globulin has",
"    <strong>",
"     no",
"    </strong>",
"    role for CMV prophylaxis when given alone, since it has been shown not to be of benefit in this setting [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2592809\">",
"    <span class=\"h3\">",
"     Approach to prophylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following recommendations are based upon the various guidelines that have been published, and the randomized trial described above [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/7-9,29\">",
"     7-9,29",
"    </a>",
"    ]. However, the approach to prophylaxis chosen for each patient depends upon protocols developed at each transplant center. (See",
"    <a class=\"local\" href=\"#H572193\">",
"     'Guidelines'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H2592782\">",
"     'Valganciclovir'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In the immediate post-transplant period, patients who are seropositive for CMV or who received an organ from a seropositive donor (CMV",
"    <span class=\"nowrap\">",
"     D+/R+,",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     D-/R+,",
"    </span>",
"    <span class=\"nowrap\">",
"     D+/R-)",
"    </span>",
"    should receive intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    once daily, with dose adjustment for renal insufficiency. Once the patient is absorbing oral medications or at hospital discharge, ganciclovir can be switched to oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    900 mg once daily, with dose adjustment for renal insufficiency.",
"   </p>",
"   <p>",
"    The 2010 Transplantation Society International CMV Consensus Group guidelines recommended at least 6 months of prophylaxis for CMV",
"    <span class=\"nowrap\">",
"     D+/R-",
"    </span>",
"    lung transplant recipients, and three to six months in CMV",
"    <span class=\"nowrap\">",
"     D+/R+",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     D-/R+",
"    </span>",
"    individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8\">",
"     8",
"    </a>",
"    ]. However, based on the clinical trial discussed above, which was published after the guidelines were released, some experts extend prophylaxis for 12 months following transplantation in all patients except those who are CMV",
"    <span class=\"nowrap\">",
"     D-/R-",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/29\">",
"     29",
"    </a>",
"    ]. Others recommend 6 months of prophylaxis followed by a preemptive approach with close monitoring of CMV viral load. The decision of which duration to give depends upon several factors, including the patient&rsquo;s risk of CMV reactivation, development of drug toxicity, and the feasibility of frequent viral load monitoring. (See",
"    <a class=\"local\" href=\"#H1635497496\">",
"     'Preemptive therapy'",
"    </a>",
"    below.) &nbsp;",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     Valganciclovir",
"    </a>",
"    prophylaxis should also be given to patients who are seropositive for CMV or who received an organ from a seropositive donor and who are receiving antilymphocyte antibodies or high doses of glucocorticoids for rejection, since such patients are at increased risk of CMV infection; prophylaxis should be continued for one to three months after the anti-rejection therapy has been completed [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H75824932\">",
"     'Risk factors'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24901?source=see_link\">",
"     cytomegalovirus immune globulin",
"    </a>",
"    (CytoGam) can be considered for CMV prophylaxis in high-risk patients (eg, CMV",
"    <span class=\"nowrap\">",
"     D+/R-,",
"    </span>",
"    <span class=\"nowrap\">",
"     D+/R+,",
"    </span>",
"    <span class=\"nowrap\">",
"     D-/R+;",
"    </span>",
"    particularly in those receiving a lymphocyte-depleting agent). We favor the use of CMV immune globulin as an adjunct to antiviral prophylaxis in such patients. (See",
"    <a class=\"local\" href=\"#H46530082\">",
"     'CMV immune globulin'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1635497496\">",
"    <span class=\"h2\">",
"     Preemptive therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using the preemptive approach, patients are monitored frequently with a CMV viral load or antigenemia assay, and antiviral therapy is initiated when viral replication has reached a certain assay threshold defined at each institution [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8\">",
"     8",
"    </a>",
"    ]. For asymptomatic CMV viremia, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    has supplanted intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    as the drug of choice.",
"   </p>",
"   <p>",
"    The preemptive approach is predicated upon a convenient, reliable surveillance test that identifies infection prior to the emergence of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8\">",
"     8",
"    </a>",
"    ]. The most widely used screening tests for this purpose are the rapid detection methods for CMV viremia and antigenemia. Evidence of CMV replication usually precedes overt clinical findings, and therapy given at this point can potentially abort the development of CMV disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/14\">",
"     14",
"    </a>",
"    ]. Preemptive therapy has some potential advantages over universal prophylaxis. Because only recipients with infection receive preemptive therapy, fewer patients are treated for a shorter duration. The net decrease in drug usage and exposure could decrease costs, drug-related toxicity, catheter-related complications, and the evolution of drug-resistant strains of CMV. However, preemptive therapy is not used commonly in lung transplant recipients during the early post-transplant period, given the high risk of CMV infection in such patients, and the limited data about its efficacy in this population. In one trial of renal transplant recipients, prophylaxis was more effective than preemptive therapy for preventing CMV disease and resulted in higher rates of graft survival [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Given the lack of data regarding the preemptive approach and the high risk of CMV infection and disease in lung transplant recipients, we do not recommend the preemptive approach during the early post-transplant period. Instead, a preemptive approach can be used after the period of prophylaxis has ended. Protocols for preemptive therapy should be developed and validated at each transplant center [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8\">",
"     8",
"    </a>",
"    ]. Recommendations for viral load monitoring are discussed above. (See",
"    <a class=\"local\" href=\"#H695482\">",
"     'CMV replication assays'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    When indicated, treatment should consist of either",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"     valganciclovir",
"    </a>",
"    900 mg orally twice daily or intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"     ganciclovir",
"    </a>",
"    5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every 12 hours, and should continue until the viral load becomes undetectable by a sensitive monitoring assay; testing during treatment is usually performed once or twice a week [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link&amp;anchor=H709588918#H709588918\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\", section on 'CMV viremia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50073781\">",
"    <span class=\"h2\">",
"     Other approaches",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50073823\">",
"    <span class=\"h3\">",
"     Blood products",
"    </span>",
"    &nbsp;&mdash;&nbsp;CMV seronegative (CMV",
"    <span class=\"nowrap\">",
"     D-/R-)",
"    </span>",
"    lung transplant recipients should receive only CMV-negative or leukoreduced blood products to decrease the risk of transfusion-related CMV transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link&amp;anchor=H11#H11\">",
"     \"Leukoreduction to prevent complications of blood transfusion\", section on 'Viral diseases'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6819183\">",
"    <span class=\"h3\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several CMV vaccines have been developed, but none are available for clinical use [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/8,41\">",
"     8,41",
"    </a>",
"    ]. Use of a live-attenuated CMV Towne strain vaccine in seronegative patients prior to renal transplantation with seropositive organs did not decrease the overall incidence of CMV infection or disease [",
"    <a class=\"abstract\" href=\"UTD.htm?5/59/6073/abstract/42\">",
"     42",
"    </a>",
"    ]. However, severe cases of CMV disease were less common among vaccinated versus placebo-treated patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4591324\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cytomegalovirus (CMV) remains an important cause of morbidity and mortality in lung transplant recipients. (See",
"      <a class=\"local\" href=\"#H1635497404\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMV infection following transplantation can be acquired in one of several ways:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      By transmission with the donor organ from a CMV-seropositive donor",
"     </li>",
"     <li>",
"      By transfusion of blood products from a CMV-seropositive blood donor",
"     </li>",
"     <li>",
"      By reactivation of latent infection in a CMV-seropositive recipient",
"     </li>",
"     <li>",
"      By close physical contact with a CMV-infected individual (see",
"      <a class=\"local\" href=\"#H1635497410\">",
"       'Epidemiology'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Guidelines for the management of CMV in solid organ transplantation were published by the American Society of Transplantation in 2009 and by the Transplantation Society International CMV Consensus Group in 2010. In addition, recommendations for the management of CMV infection in lung transplant recipients were published in 2005. (See",
"      <a class=\"local\" href=\"#H572193\">",
"       'Guidelines'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMV infection is defined as evidence of CMV replication regardless of symptoms. (See",
"      <a class=\"local\" href=\"#H572056\">",
"       'Infection versus disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMV disease is defined as evidence of CMV infection with attributable symptoms; CMV disease may manifest as either a viral syndrome with fever, malaise, leukopenia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      thrombocytopenia, or as tissue invasive disease. (See",
"      <a class=\"local\" href=\"#H572056\">",
"       'Infection versus disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most important risk factor for CMV infection and disease in lung transplant recipients is CMV serologic status, with seronegative recipients of seropositive organs (CMV",
"      <span class=\"nowrap\">",
"       D+/R-)",
"      </span>",
"      having the highest risk. The use of anti-lymphocyte antibodies as induction therapy or for the treatment of steroid-resistant rejection is associated with an increase in CMV replication and the development of CMV disease in seropositive recipients. (See",
"      <a class=\"local\" href=\"#H75824932\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend universal prophylaxis against CMV with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      rather than preemptive therapy for all lung transplant recipients who are CMV seropositive or who received an organ from a seropositive donor (CMV",
"      <span class=\"nowrap\">",
"       D+/R+,",
"      </span>",
"      <span class=\"nowrap\">",
"       D-/R+,",
"      </span>",
"      <span class=\"nowrap\">",
"       D+/R-)",
"      </span>",
"      (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). In the immediate post-transplant period, patients should receive intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/30/33248?source=see_link\">",
"       ganciclovir",
"      </a>",
"      5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      once daily, with dose adjustment for renal insufficiency. Once the patient is absorbing oral medications or at hospital discharge, ganciclovir can be switched to oral valganciclovir 900 mg once daily, with dose adjustment for renal insufficiency. (See",
"      <a class=\"local\" href=\"#H2592809\">",
"       'Approach to prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some experts recommend continuing CMV prophylaxis for 12 months following transplantation in recipients who are CMV-seropositive or who received an organ from a seropositive donor, but others prefer to give only 6 months of prophylaxis followed by a preemptive approach with frequent monitoring of CMV viral load. The decision of which duration to give depends upon several factors, including the patient&rsquo;s risk of CMV reactivation, development of drug toxicity, and the feasibility of frequent viral load monitoring. (See",
"      <a class=\"local\" href=\"#H2592809\">",
"       'Approach to prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend CMV prophylaxis with oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/37/5718?source=see_link\">",
"       valganciclovir",
"      </a>",
"      for lung transplant recipients who are CMV seropositive or who received an organ from a seropositive donor (CMV",
"      <span class=\"nowrap\">",
"       D+/R+,",
"      </span>",
"      <span class=\"nowrap\">",
"       D-/R+,",
"      </span>",
"      <span class=\"nowrap\">",
"       D+/R-)",
"      </span>",
"      with rejection who are receiving antilymphocyte antibodies or high doses of glucocorticoids (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). Prophylaxis should be continued for one to three months after the anti-rejection therapy has been completed. (See",
"      <a class=\"local\" href=\"#H2592809\">",
"       'Approach to prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An alternative to CMV prophylaxis is preemptive therapy, in which antiviral therapy is initiated if viral replication has reached a certain assay threshold defined at each institution. However, preemptive therapy is not used commonly during the early post-transplant period in lung transplant recipients, given the high risk of CMV infection in such patients, and the limited data about its efficacy in this population. A preemptive approach is more often used after the period of prophylaxis has ended. (See",
"      <a class=\"local\" href=\"#H1635497496\">",
"       'Preemptive therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest using",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/20/24901?source=see_link\">",
"       cytomegalovirus immune globulin",
"      </a>",
"      (CytoGam) as an adjunct to antiviral prophylaxis in high-risk lung transplant recipients (eg, CMV",
"      <span class=\"nowrap\">",
"       D+/R-,",
"      </span>",
"      <span class=\"nowrap\">",
"       D+/R+,",
"      </span>",
"      <span class=\"nowrap\">",
"       D-/R+;",
"      </span>",
"      particularly in those receiving a lymphocyte-depleting agent)(",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, some experts do not use CMV immune globulin as part of the prophylactic regimen since its efficacy has not been clearly established. (See",
"      <a class=\"local\" href=\"#H46530082\">",
"       'CMV immune globulin'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2592809\">",
"       'Approach to prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CMV seronegative (CMV",
"      <span class=\"nowrap\">",
"       D-/R-)",
"      </span>",
"      lung transplant recipients should receive only CMV-negative or leukoreduced blood products to decrease the risk of transfusion-related CMV transmission. (See",
"      <a class=\"local\" href=\"#H50073823\">",
"       'Blood products'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/1\">",
"      Pereyra F, Rubin RH. Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients. Curr Opin Infect Dis 2004; 17:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/2\">",
"      Balfour HH Jr. Cytomegalovirus: the troll of transplantation. Arch Intern Med 1979; 139:279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/3\">",
"      Zamora MR. Cytomegalovirus and lung transplantation. Am J Transplant 2004; 4:1219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/4\">",
"      Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/5\">",
"      Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: a systematic review of recent publications. J Heart Lung Transplant 2002; 21:271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/6\">",
"      Tamm M, Aboyoun CL, Chhajed PN, et al. Treated cytomegalovirus pneumonia is not associated with bronchiolitis obliterans syndrome. Am J Respir Crit Care Med 2004; 170:1120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/7\">",
"      Humar A, Snydman D, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients. Am J Transplant 2009; 9 Suppl 4:S78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/8\">",
"      Kotton CN, Kumar D, Caliendo AM, et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010; 89:779.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/9\">",
"      Zamora MR, Davis RD, Leonard C, CMV Advisory Board Expert Committee. Management of cytomegalovirus infection in lung transplant recipients: evidence-based recommendations. Transplantation 2005; 80:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/10\">",
"      Ljungman P, Griffiths P, Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002; 34:1094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/11\">",
"      Hibberd PL, Tolkoff-Rubin NE, Cosimi AB, et al. Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3. Transplantation 1992; 53:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/12\">",
"      Jamil B, Nicholls KM, Becker GJ, Walker RG. Influence of anti-rejection therapy on the timing of cytomegalovirus disease and other infections in renal transplant recipients. Clin Transplant 2000; 14:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/13\">",
"      Cope AV, Sabin C, Burroughs A, et al. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997; 176:1484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/14\">",
"      Ettinger NA, Bailey TC, Trulock EP, et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Washington University Lung Transplant Group. Am Rev Respir Dis 1993; 147:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/15\">",
"      Duncan AJ, Dummer JS, Paradis IL, et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant 1991; 10:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/16\">",
"      Balthesen M, Messerle M, Reddehase MJ. Lungs are a major organ site of cytomegalovirus latency and recurrence. J Virol 1993; 67:5360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/17\">",
"      Glanville AR, Valentine VG, Aboyoun CL, Malouf MA. CMV mismatch is not a risk factor for survival or severe bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2004; 23:S43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/18\">",
"      Zamora MR. Controversies in lung transplantation: management of cytomegalovirus infections. J Heart Lung Transplant 2002; 21:841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/19\">",
"      Paradis IL, Williams P. Infection after lung transplantation. Semin Respir Infect 1993; 8:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/20\">",
"      Seed CR, Piscitelli LM, Maine GT, et al. Validation of an automated immunoglobulin G-only cytomegalovirus (CMV) antibody screening assay and an assessment of the risk of transfusion transmitted CMV from seronegative blood. Transfusion 2009; 49:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/21\">",
"      Weber B, Fall EM, Berger A, Doerr HW. Screening of blood donors for human cytomegalovirus (HCMV) IgG antibody with an enzyme immunoassay using recombinant antigens. J Clin Virol 1999; 14:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/22\">",
"      Lazzarotto T, Brojanac S, Maine GT, Landini MP. Search for cytomegalovirus-specific immunoglobulin M: comparison between a new western blot, conventional western blot, and nine commercially available assays. Clin Diagn Lab Immunol 1997; 4:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/23\">",
"      Bando K, Paradis IL, Komatsu K, et al. Analysis of time-dependent risks for infection, rejection, and death after pulmonary transplantation. J Thorac Cardiovasc Surg 1995; 109:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/24\">",
"      Duncan SR, Paradis IL, Dauber JH, et al. Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients. Am Rev Respir Dis 1992; 146:1213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/25\">",
"      Bailey TC, Ettinger NA, Storch GA, et al. Failure of high-dose oral acyclovir with or without immune globulin to prevent primary cytomegalovirus disease in recipients of solid organ transplants. Am J Med 1993; 95:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/26\">",
"      Duncan SR, Grgurich WF, Iacono AT, et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994; 150:146.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/27\">",
"      Guti&eacute;rrez CA, Chaparro C, Krajden M, et al. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest 1998; 113:924.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/28\">",
"      Bailey TC, Trulock EP, Ettinger NA, et al. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis 1992; 165:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/29\">",
"      Palmer SM, Limaye AP, Banks M, et al. Extended valganciclovir prophylaxis to prevent cytomegalovirus after lung transplantation: a randomized, controlled trial. Ann Intern Med 2010; 152:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/30\">",
"      Palmer SM, Grinnan DC, Diane Reams B, et al. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir. Clin Transplant 2004; 18:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/31\">",
"      Zamora MR, Nicolls MR, Hodges TN, et al. Following universal prophylaxis with intravenous ganciclovir and cytomegalovirus immune globulin, valganciclovir is safe and effective for prevention of CMV infection following lung transplantation. Am J Transplant 2004; 4:1635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/32\">",
"      Paya C, Humar A, Dominguez E, et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004; 4:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/33\">",
"      Jaksch P, Zweytick B, Kerschner H, et al. Cytomegalovirus prevention in high-risk lung transplant recipients: comparison of 3- vs 12-month valganciclovir therapy. J Heart Lung Transplant 2009; 28:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/34\">",
"      Chmiel C, Speich R, Hofer M, et al. Ganciclovir/valganciclovir prophylaxis decreases cytomegalovirus-related events and bronchiolitis obliterans syndrome after lung transplantation. Clin Infect Dis 2008; 46:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/35\">",
"      Finlen Copeland CA, Davis WA, Snyder LD, et al. Long-term efficacy and safety of 12 months of valganciclovir prophylaxis compared with 3 months after lung transplantation: a single-center, long-term follow-up analysis from a randomized, controlled cytomegalovirus prevention trial. J Heart Lung Transplant 2011; 30:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/36\">",
"      Emery VC, Griffiths PD. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci U S A 2000; 97:8039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/37\">",
"      McGavin JK, Goa KL. Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs 2001; 61:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/38\">",
"      Valantine HA, Luikart H, Doyle R, et al. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone. Transplantation 2001; 72:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/39\">",
"      Kruger RM, Paranjothi S, Storch GA, et al. Impact of prophylaxis with cytogam alone on the incidence of CMV viremia in CMV-seropositive lung transplant recipients. J Heart Lung Transplant 2003; 22:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/40\">",
"      Kliem V, Fricke L, Wollbrink T, et al. Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial. Am J Transplant 2008; 8:975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/41\">",
"      Gandhi MK, Khanna R. Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. Lancet Infect Dis 2004; 4:725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?5/59/6073/abstract/42\">",
"      Plotkin SA, Higgins R, Kurtz JB, et al. Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 1994; 58:1176.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8313 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-F35B292492-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6073=[""].join("\n");
var outline_f5_59_6073=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4591324\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1635497404\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1635497410\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H572193\">",
"      GUIDELINES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H572056\">",
"      INFECTION VERSUS DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H75824932\">",
"      RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1635497416\">",
"      Serologic status",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1635497428\">",
"      DIAGNOSTIC TESTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5471661\">",
"      Pre-transplant serologic testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H695482\">",
"      CMV replication assays",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1635497466\">",
"      PREVENTION OF DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H572572\">",
"      Universal prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2592775\">",
"      - Ganciclovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2592782\">",
"      - Valganciclovir",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H46530082\">",
"      - CMV immune globulin",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2592809\">",
"      - Approach to prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1635497496\">",
"      Preemptive therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50073781\">",
"      Other approaches",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H50073823\">",
"      - Blood products",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6819183\">",
"      - Vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4591324\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/25/8597?source=related_link\">",
"      Diagnosis of cytomegalovirus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/25/13722?source=related_link\">",
"      Epidemiology, clinical manifestations, and treatment of cytomegalovirus infection in immunocompetent hosts",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/25/17815?source=related_link\">",
"      Ganciclovir and valganciclovir: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=related_link\">",
"      Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=related_link\">",
"      Tuberculosis in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=related_link\">",
"      Viral load testing for cytomegalovirus in solid organ transplant recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_59_6074="Itraconazole: Pediatric drug information";
var content_f5_59_6074=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Itraconazole: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"    see \"Itraconazole: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?33/17/34069?source=see_link\">",
"    see \"Itraconazole: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F5708958\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F185420\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Onmel&trade;;",
"     </li>",
"     <li>",
"      Sporanox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F185421\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Sporanox&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antifungal Agent, Systemic",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block don drugH1Div\" id=\"F12857579\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Neonatal",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"     <b>",
"      Note:",
"     </b>",
"     Limited data available; further studies are needed, consider alternative agents.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Tinea capitis (",
"      <i>",
"       Microsporum canis",
"      </i>",
"      )",
"     </b>",
"     : Oral solution: 5 mg/kg/dose once daily for 6 weeks was used in a single, full-term neonate as part of a larger open-label pilot study of seven infants (age: 3-46 weeks) who received therapy for 3-6 weeks (Binder, 2009)",
"    </p>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048110\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=see_link\">",
"      see \"Itraconazole: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Infants and Children:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      General dosing:",
"     </b>",
"     Limited data available: Usual reported range: 3-5 mg/kg/dose once daily; doses as high as 5-10 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided every 12-24 hours have been used in 32 patients with chronic granulomatous disease for prophylaxis against Aspergillus infection; doses of 6-8 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     have been used in the treatment of disseminated histoplasmosis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Candidiasis",
"      </i>",
"      (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oropharyngeal, treatment: Oral solution: 2.5 mg/kg/dose twice daily for 7-14 days (maximum daily dose: 200 mg/",
"     <b>",
"      day",
"     </b>",
"     or 400 mg/",
"     <b>",
"      day",
"     </b>",
"     if fluconazole-refractory)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Esophageal, treatment: Oral solution: 5 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided once or twice daily for 4-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Coccidioidomycosis",
"      </i>",
"      , disseminated, non-CNS (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment: Oral: 5-10 mg/kg/dose twice daily for 3 days followed by 2-5 mg/kg/dose twice daily  (maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"     ); product formulation not specified",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Relapse prevention: 2-5 mg/kg/dose twice daily (maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"     ); product formulation not specified",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Crypotococcus",
"      </i>",
"      (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment, consolidation therapy: Oral solution (preferred): Initial load: 2.5-5 mg/kg/dose 3 times daily (maximum daily dose: 600 mg/",
"     <b>",
"      day)",
"     </b>",
"     for 3 days (9 doses) followed by  5-10 mg/kg/",
"     <b>",
"      day",
"     </b>",
"     divided once or twice daily (maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"     ) for a minimum of 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Relapse prevention: Oral solution: 5 mg/kg/dose once daily (maximum daily dose: 200 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Histoplasmosis",
"      </i>",
"      (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Treatment, mild disseminated disease: Oral solution: 2-5 mg/kg/dose 3 times daily for 3 days (9 doses) followed by 2-5 mg/kg/dose twice daily for 12 months (maximum dose: 200 mg/dose)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Consolidation treatment for moderate-severe to severe disseminated disease, including CNS infection (following appropriate induction therapy): Oral solution:  2-5 mg/kg/dose 3 times daily for 3 days (9 doses) followed by 2-5 mg/kg/dose (maximum dose: 200 mg/dose) twice daily for 12 months for non-CNS disseminated disease or for &ge;12 months for CNS infection as determined by clinical response.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Relapse prevention: Oral solution: 5 mg/kg/dose twice daily (maximum daily dose: 400 mg/",
"     <b>",
"      day",
"     </b>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Tinea capitis (",
"      <i>",
"       Microsporum canis",
"      </i>",
"      ):",
"     </b>",
"     Oral solution or capsules: 5 mg/kg/dose once daily for 3-6 weeks was used in a small open-label pilot study of seven infants (age: 3-46 weeks); if capsules were used, they were opened and sprinkled on main meal of the day (Binder, 2009)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adolescents:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      General dosing:",
"     </b>",
"     100-600 mg/",
"     <b>",
"      day",
"     </b>",
"     ; doses &gt;200 mg/",
"     <b>",
"      day",
"     </b>",
"     are usually  given in 2 divided doses; length of therapy varies from 1 day to &gt;6 months depending on the condition and mycological response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Candidiasis",
"      </i>",
"      (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Oropharyngeal, treatment: Oral solution: 200 mg once daily for 7-14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Esophageal, treatment: Oral solution: 200 mg once daily for 14-21 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Vulvovaginal, uncomplicated: Oral solution: 200 mg once daily for 3-7 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Coccidioidomycosis",
"      </i>",
"      (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild infection, treatment (eg, focal pneumonia): 200 mg 3 times daily for 3 days followed by 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Meningitis:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Treatment: 200 mg 3 times daily for 3 days followed by 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Maintenance therapy: 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:8em;text-align:justify;\">",
"     Prevention of first episode: 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Crypotococcus",
"      </i>",
"      (CNS disease, meningitis) (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Consolidation therapy: 200 mg twice daily for 8 weeks or as determined by target CD4+ counts; may be initiated after at least 2 weeks of successful induction therapy (eg, significant clinical improvement and negative CSF culture )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance therapy: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Histoplasmosis",
"      </i>",
"      (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a):",
"     <b>",
"      Note:",
"     </b>",
"     Monitoring of serum concentrations recommended to ensure adequate absorption.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild disseminated disease, treatment: Oral solution (preferred): 200 mg 3 times/day for 3 days, then 200 mg twice daily for at least 12 months",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Moderate to severe non-CNS disease, maintenance therapy: Oral solution (preferred): 200 mg 3 times/day for 3 days, then 200 mg twice daily following amphotericin B induction therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Meningitis, maintenance therapy: Oral solution (preferred): 200 mg twice daily or 3 times/day for &ge;1 year following liposomal amphotericin B induction therapy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Long-term suppression therapy: Oral solution (preferred): 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Prevention of first episode: Oral solution (preferred): 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Microsporidiosis",
"      </i>",
"      , treatment disseminated disease (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a): 400 mg once daily in conjunction with albendazole",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Penicilliosis (HIV-exposed/-positive)",
"     </b>",
"     (CDC, 2009a):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Acute infection (severely ill), maintenance therapy:  400 mg once daily for 10 weeks; initiate after completion of  2 weeks induction  therapy with amphotericin B",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Mild disease, treatment: 400 mg once daily for 8 weeks",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     Maintenance therapy: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 100-800 mg/",
"     <b>",
"      day",
"     </b>",
"     ; doses &gt;200 mg/",
"     <b>",
"      day",
"     </b>",
"     are usually given in 2 divided doses; length of therapy varies from 1 day to &gt;6 months depending on the condition and mycological response",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in renal impairment:",
"     </b>",
"     The FDA-approved labeling states to use with caution in patients with renal impairment. The following guidelines have been used by some clinicians: Adults (Aronoff, 2007):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &gt;10 mL/minute: No adjustment recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;10 mL/minute: Administer 50% of normal dose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Poorly dialyzed; no supplemental dose or dosage adjustment necessary, including patients on intermittent hemodialysis, peritoneal dialysis, or continuous renal replacement therapy (eg, CVVHD).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Dosing adjustment in hepatic impairment:",
"     </b>",
"     Use caution.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F185395\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sporanox&reg;: 100 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Sporanox&reg;: 10 mg/mL (150 mL) [contains propylene glycol; cherry-caramel flavor]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Onmel&trade;: 200 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F185380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes: Capsule",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F15674161\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Onmel&trade; 200 mg tablets: FDA approved November 2012; availability anticipated January 2013. Onmel&trade; is indicated for the treatment of onychomycosis of the toenail; consult prescribing information for additional information.",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048122\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Oral: Doses &gt;200 mg/day are given in 2 divided doses; do not administer with antacids.",
"     <b>",
"      Capsule and oral solution formulations are not bioequivalent and thus are not interchangeable.",
"     </b>",
"     Capsule absorption is best if taken with food, therefore, it is best to administer itraconazole after meals; solution should be taken on an empty stomach. When treating oropharyngeal and esophageal candidiasis, solution should be swished vigorously in mouth, then swallowed.",
"    </p>",
"   </div>",
"   <div class=\"block sta drugH1Div\" id=\"F1048113\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Stability",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Capsules: Store at controlled room temperature 15&deg; to 25&deg;C (59&deg;F to 77&deg;F). Protect from light and moisture.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral solution: Store at or below 25&deg;C (77&deg;F). Do not freeze.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048121\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of susceptible systemic fungal infections in immunocompromised and nonimmunocompromised patients including blastomycosis, coccidioidomycosis, paracoccidioidomycosis, histoplasmosis, and aspergillosis in patients who do not respond to or cannot tolerate amphotericin B (FDA approved in adults); treatment of oropharyngeal or esophageal candidiasis (oral solution only) (FDA approved in adults)",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F185476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Itraconazole may be confused with fluconazole",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Sporanox&reg; may be confused with Suprax&reg;, Topamax&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F185473\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Chest pain, edema, hypertension",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, depression, dizziness, dreams abnormal, fatigue, fever, headache, malaise, pain",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Hypertriglyceridemia, hypokalemia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal pain, appetite increased, constipation, dyspepsia, flatulence, gastritis, gastroenteritis, gingivitis, stomatitis (ulcerative), vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hepatic: LFTs abnormal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Bursitis, myalgia, tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Renal: Cystitis, urinary tract infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Cough, dyspnea, pharyngitis, pneumonia, rhinitis, sinusitis, sputum increased, upper respiratory infection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis increased, herpes zoster",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Adrenal insufficiency, albuminuria, allergic reactions, alopecia, anaphylactoid reactions, anaphylaxis, angioedema, anorexia, arrhythmia, arthralgia, blurred vision, dehydration, diplopia, dysgeusia, dysphagia, erythema multiforme, exanthematous pustulosis, exfoliative dermatitis, gynecomastia, hearing loss, heart failure, hematuria, hepatic failure, hepatitis, hepatotoxicity, hot flashes, hypoesthesia, impotence, insomnia, leukocytoclastic dermatitis, leukopenia, libido decreased, menstrual disorders, neutropenia, pancreatitis, paresthesia, peripheral edema, photosensitivity, pollakiuria, pulmonary edema, rigors, serum sickness, somnolence, Stevens-Johnson syndrome, thrombocytopenia, taste perversion, tinnitus, toxic epidermal necrolysis, urinary incontinence, urticaria, vasculitis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048125\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to itraconazole or any component; concurrent administration with cisapride, dofetilide, ergot derivatives, levomethadyl, lovastatin, midazolam (oral), nisoldipine, pimozide, quinidine, simvastatin, or triazolam; treatment of onychomycosis in patients with evidence of left ventricular dysfunction, CHF, a history of CHF, pregnant women, or women intending to become pregnant",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048109\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with hypersensitivity to other azole antifungal agents, patients with left ventricular dysfunction or a history of CHF, and in patients with hepatic impairment; discontinue if signs and symptoms of liver disease or CHF develop. Large differences in itraconazole pharmacokinetic parameters have been observed in cystic fibrosis patients receiving the solution; if a patient with cystic fibrosis does not respond to therapy, alternate therapies should be considered. Transient or permanent hearing loss has been reported. Quinidine (a contraindicated drug) was used concurrently in several of these cases. Hearing loss usually resolves after discontinuation, but may persist in some patients.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1048108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Not recommended for treatment of onychomycosis in patients with left ventricular dysfunction or a history of CHF",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Negative inotropic effects have been observed following intravenous administration. Discontinue or reassess use if signs or symptoms of CHF occur during treatment",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Calcium channel blockers (CCBs) may cause additive negative inotropic effects when used concurrently with itraconazole. Itraconazole may also inhibit the metabolism of CCBs; therefore, use caution with concurrent use of itraconazole and CCBs due to an increased risk of heart failure.  Coadministration of cisapride, pimozide, quinidine, dofetilide, or levacetylmethadol (levomethadyl) with itraconazole is contraindicated",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     . Rare cases of serious cardiovascular adverse events (including death), ventricular tachycardia, and torsade de pointes have been observed due to increased cisapride, pimozide, quinidine, dofetilide, or levomethadyl concentrations induced by itraconazole. Serious (and rarely fatal) hepatic toxicity (eg, hepatitis, cholestasis, fulminant failure) has been observed with azole therapy; monitor liver function closely and dosage adjustment may be warranted. Not recommended for use in patients with active liver disease, elevated liver enzymes, or prior hepatotoxic reactions to other drugs.",
"     <b>",
"      Due to differences in bioavailability, itraconazole solution and capsules should not be used interchangeably",
"     </b>",
"     . The oral solution contains propylene glycol; in neonates large amounts of propylene glycol (eg, &gt;3000 mg/day I.V.) have been associated with potentially fatal toxicities which can include metabolic acidosis, seizures, renal failure, and CNS depression; use forms containing propylene glycol with caution in neonates.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F185462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP3A4 (major);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP3A4 (strong), P-glycoprotein",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F185389\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ado-Trastuzumab Emtansine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Ado-Trastuzumab Emtansine. Specifically, strong CYP3A4 inhibitors may increase concentrations of the cytotoxic DM1 component.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfentanil: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Alfentanil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alfuzosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alfuzosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aliskiren: Itraconazole may increase the serum concentration of Aliskiren.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Almotriptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Almotriptan.  Management: Limit initial almotriptan adult dose to 6.25 mg and maximum adult dose to 12.5 mg/24-hrs when used with a strong CYP3A4 inhibitor. Avoid concurrent use in patients with impaired hepatic or renal function.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alosetron: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Alosetron.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Amphotericin B: Antifungal Agents (Azole Derivatives, Systemic) may diminish the therapeutic effect of Amphotericin B.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Itraconazole. Management: Administer itraconazole at least 1 hour after and 2 hours before administration of any antacids.  Itraconazole oral suspension may be less sensitive to the effects of decreased gastric acidity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Apixaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Apixaban.  Management: Apixaban U.S. prescribing information states dose reduction criteria that may be applied under some circumstances. The apixaban Canadian product monograph suggests that any combined use is contraindicated. See full interaction monograph for details.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aprepitant: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Aprepitant.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Strong) may increase the serum concentration of ARIPiprazole.  Management: See full interaction monograph for details.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtorvaSTATin: Itraconazole may increase the serum concentration of AtorvaSTATin.  Management: Limit atorvastatin to a maximum adult dose of 20 mg/day in patients receiving itraconazole.  Assess clinical response to ensure that the lowest necessary dose of atorvastatin is used. Consider use of fluva-, rosuva-, pitava-, or pravastatin when possible.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Avanafil: Itraconazole may increase the serum concentration of Avanafil.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Axitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Axitinib.  Management: Avoid concurrent use of axitinib with any strong CYP3A inhibitor whenever possible.  If a strong CYP3A inhibitor must be used with axitinib, a 50% axitinib dose reduction is recommended.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bedaquiline: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bedaquiline.  Management: Limit the duration of concomitant administration of bedaquiline with CYP3A4 inhibitors to no more than 14 days, unless the benefit of continued administration is judged to outweigh the possible risks. Monitor for toxic effects of bedaquiline.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Benzodiazepines (metabolized by oxidation): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Benzodiazepines (metabolized by oxidation).  Management: The following combinations are specifically contraindicated: itraconazole with alprazolam, estazolam, oral midazolam, or triazolam; ketoconazole with alprazolam, estazolam, or triazolam.  Consider initial dose reductions of other benzodiazepines.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Quazepam.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Boceprevir: May increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Boceprevir. Management: Limit maximum adult itraconazole dose to 200 mg daily in patients receiving boceprevir, due to a possible increase in itraconazole concentrations.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bortezomib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bortezomib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosentan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Bosentan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bosutinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Bosutinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brentuximab Vedotin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brentuximab Vedotin. Specifically, concentrations of the active monomethyl auristatin E (MMAE) component may be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Brinzolamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Brinzolamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Budesonide (Systemic, Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Budesonide (Systemic, Oral Inhalation).  Management: Consider reducing the oral budesonide dose when used together with a CYP3A4 inhibitor.  This interaction is likely less severe with orally inhaled budesonide.  Monitor patients closely for signs/symptoms of corticosteroid excess.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     BusPIRone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of BusPIRone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Busulfan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Busulfan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cabozantinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Cabozantinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Calcium Channel Blockers: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Calcium Channel Blockers. Specifically, itraconazole may enhance the negative inotropic effects of verapamil or diltiazem. Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Calcium Channel Blockers.  Management: Concurrent use of felodipine or nisoldipine with itraconazole is specifically contraindicated.  Frequent monitoring is warranted with any such combination; calcium channel blocker dose reductions may be required.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Clevidipine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CarBAMazepine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CarBAMazepine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cardiac Glycosides: Itraconazole may increase the serum concentration of Cardiac Glycosides.  Management: Consider preemptive cardiac glycoside dose adjustments with initiation / changes / discontinuation of itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cilostazol: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Cilostazol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cisapride: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Cisapride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cobicistat: May increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Cobicistat. Management: Limit itraconazole to a maximum dose of 200 mg/day in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Colchicine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Colchicine.  Management: Colchicine is contraindicated in patients with impaired renal or hepatic function who are also receiving a strong CYP3A4 inhibitor.  In those with normal renal and hepatic function, reduce colchicine dose as directed.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Conivaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Conivaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Orally Inhaled): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Corticosteroids (Orally Inhaled).  Management: Monitor for signs and symptoms of adrenal suppression if inhaled budesonide or mometasone are coadministered with a strong CYP3A4 inhibitor.  Avoid combining inhaled fluticasone with any strong CYP3A4 inhibitor.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Oral Inhalation); Triamcinolone (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Corticosteroids (Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Crizotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Crizotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CycloSPORINE (Systemic): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of CycloSPORINE (Systemic).",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Inducers (Strong): May decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CYP3A4 Substrates: CYP3A4 Inhibitors (Strong) may decrease the metabolism of CYP3A4 Substrates.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dabigatran Etexilate: P-glycoprotein/ABCB1 Inhibitors may increase serum concentrations of the active metabolite(s) of Dabigatran Etexilate.  Management: Dabigatran dose reductions may be needed.  Specific recommendations vary considerably according to US vs Canadian labeling, specific P-gp inhibitor, renal function, and indication for dabigatran treatment.  Refer to full monograph or dabigatran labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Darunavir: May increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Darunavir. Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving darunavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferasirox: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Didanosine: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic). Enteric coated didanosine capsules are not expected to affect these antifungals.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dienogest: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dienogest.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dihydroergotamine: Itraconazole may increase the serum concentration of Dihydroergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     DOCEtaxel: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of DOCEtaxel.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dofetilide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Dofetilide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dronedarone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dronedarone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dutasteride: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Dutasteride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Efavirenz: May decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eletriptan: Itraconazole may increase the serum concentration of Eletriptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Elvitegravir: Itraconazole may increase the serum concentration of Elvitegravir.  Management: Limit itraconazole to a maximum dose of 200 mg/day in patients who are being treated with the elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate combination product.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Enzalutamide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Enzalutamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eplerenone: Itraconazole may increase the serum concentration of Eplerenone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergoloid Mesylates: Itraconazole may increase the serum concentration of Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergonovine: Itraconazole may increase the serum concentration of Ergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergotamine: Itraconazole may increase the serum concentration of Ergotamine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Erlotinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Erlotinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eszopiclone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Eszopiclone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Etravirine: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with itraconazole or ketoconazole. Etravirine may increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This would be anticipated with voriconazole. Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Etravirine. Management: Monitor for increased effects/toxicity of etravirine.  Antifungal dose adjustment may be needed for ketoconazole, itraconazole, or posaconazole but specific dosing guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Everolimus: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Everolimus.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Felodipine: Itraconazole may increase the serum concentration of Felodipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     FentaNYL: CYP3A4 Inhibitors (Strong) may increase the serum concentration of FentaNYL.  Management: Monitor patients extra closely for several days following initiation of the combination, and fentanyl dosage reductions should be made as appropriate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fesoterodine: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Fesoterodine.  Management: Avoid fesoterodine doses greater than 4 mg daily in adult patients who are also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fexofenadine: Itraconazole may increase the serum concentration of Fexofenadine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Nasal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fluticasone (Oral Inhalation): CYP3A4 Inhibitors (Strong) may increase the serum concentration of Fluticasone (Oral Inhalation).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosamprenavir: Itraconazole may increase serum concentrations of the active metabolite(s) of Fosamprenavir. Specifically, amprenavir concentrations may be increased. Fosamprenavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day with fosamprenavir/ritonavir. In patients receiving fosamprenavir without ritonavir, patients receiving greater than 400 mg/day itraconazole may also require dose reduction.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosaprepitant: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosaprepitant. Specifically, concentrations of aprepitant are likely to be increased.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gefitinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Gefitinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Grapefruit Juice: May increase the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). This specifically applies to oral antifungal administration, and the interaction may be different depending on specific dosage form being used.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     GuanFACINE: CYP3A4 Inhibitors (Strong) may increase the serum concentration of GuanFACINE.  Management: Reduce the guanfacine dose by 50% when adding a strong CYP3A4 inhibitor.  Limit the guanfacine dose to 2 mg/day when starting guanfacine in a patient who is taking a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Itraconazole. Management: When this combination is used, the itraconazole should be administered with a cola beverage (8 ounces). Itraconazole oral suspension may be less sensitive to this interaction.  Monitor patient response to itraconazole closely.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Halofantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Halofantrine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Herbs (CYP3A4 Inducers): May increase the metabolism of CYP3A4 Substrates. Management: Consider avoiding CYP3A4 inducing herbs in order to avoid therapeutic failure of the substrate. Some combinations may be specifically contraindicated. Consult appropriate manufacturer labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Highest Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Highest Risk QTc-Prolonging Agents.  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ifosfamide: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ifosfamide.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iloperidone: CYP3A4 Inhibitors (Strong) may increase serum concentrations of the active metabolite(s) of Iloperidone. Specifically, concentrations of the metabolites P88 and P95 may be increased. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Iloperidone.  Management: Reduce iloperidone dose by half when administered with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Imatinib: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Imatinib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Indinavir: May increase the serum concentration of Itraconazole. Itraconazole may increase the serum concentration of Indinavir. Management: Reduce the normal indinavir adult dose to 600 mg every 8 hours when given with itraconazole.  Monitor for increased systemic effects (including adverse/toxic effects) of itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Irinotecan: Antifungal Agents (Azole Derivatives, Systemic) may enhance the adverse/toxic effect of Irinotecan.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Isoniazid: May decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivabradine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivabradine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ivacaftor: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ivacaftor.  Management: Decrease ivacaftor dose to 150 mg twice a week in patients also receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ixabepilone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lapatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lapatinib.  Management: If an overlap in therapy cannot be avoided, consider reducing lapatinib dose to 500 mg/day during, and within 1 week of completing, treatment with the strong CYP3A4 inhibitor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lomitapide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lopinavir: May increase the serum concentration of Itraconazole. Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving lopinavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Losartan: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Losartan.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lovastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lovastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lumefantrine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lumefantrine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lurasidone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Lurasidone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Macrolide Antibiotics: May decrease the metabolism of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Macrolide Antibiotics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Azithromycin (Systemic); Fidaxomicin; Spiramycin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Maraviroc: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Maraviroc.  Management: Reduce the adult dose of maraviroc to 150 mg twice daily when used with a strong CYP3A4 inhibitor.  Do not use maraviroc with strong CYP3A4 inhibitors in patients with Clcr less than 30 mL/min.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methadone: Itraconazole may increase the serum concentration of Methadone.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methylergonovine: Itraconazole may increase the serum concentration of Methylergonovine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MethylPREDNISolone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of MethylPREDNISolone.  Management: Consider methylprednisolone dose titration and/or adjustments in patients receiving strong CYP3A4 inhibitors (eg, azole antifungals, protease inhibitors) and monitor for  increased steroid related adverse effects.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Midazolam: Itraconazole may increase the serum concentration of Midazolam.  Management: Oral midazolam is contraindicated.  Use intravenous midazolam with great caution in patients receiving itraconazole, employing reduced initial doses whenever possible and monitoring closely for enhanced and prolonged effects.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mifepristone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Mifepristone.  Management: Limit mifepristone adult dose, when used for treatment of hyperglycemia in Cushing's syndrome, to a maximum of 300 mg/day when combined with a strong CYP3A4 inhibitor. Monitor for increased mifepristone toxicity regardless of dose or indication.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Moderate Risk QTc-Prolonging Agents: QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of Moderate Risk QTc-Prolonging Agents.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nevirapine: May decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nilotinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nilotinib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Nisoldipine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Nisoldipine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ospemifene: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ospemifene.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paliperidone: Itraconazole may decrease the metabolism of Paliperidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paricalcitol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Paricalcitol.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pazopanib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pazopanib.  Management: Avoid concurrent use of pazopanib with strong inhibitors of CYP3A4 whenever possible.  If it is not possible to avoid such a combination, reduce pazopanib adult dose to 400 mg.  Further dose reductions may also be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     P-glycoprotein/ABCB1 Substrates: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Phenytoin. Management: Concomitant therapy with itraconazole, voriconazole, or ketoconazole and phenytoin should probably be avoided, as antifungal failure is likely.  Consider selecting alternative antifungal therapy.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimecrolimus: CYP3A4 Inhibitors (Strong) may decrease the metabolism of Pimecrolimus.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pomalidomide: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Pomalidomide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ponatinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ponatinib.  Management: Per ponatinib U.S. prescribing information, the starting dose of ponatinib should be reduced to 30 mg daily during treatment with any strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prasugrel: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Prasugrel.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pravastatin: Itraconazole may increase the serum concentration of Pravastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Propafenone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Propafenone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Prucalopride: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Prucalopride.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     QuiNIDine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of QuiNIDine.  Management: Itraconazole, voriconazole, and posaconazole are specifically contraindicated with quinidine.  Use of quinidine with any azole antifungal may require quinidine dose adjustment and should be done with caution and close monitoring.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ramelteon: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ramelteon.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ranolazine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ranolazine.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Red Yeast Rice: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Red Yeast Rice. Specifically, concentrations of lovastatin and related compounds found in Red Yeast Rice may be increased.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Regorafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Regorafenib.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Repaglinide: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Repaglinide.  Management: Concurrent use of an azole antifungal with both repaglinide and gemfibrozil should be avoided.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rifamycin Derivatives: May decrease the serum concentration of Antifungal Agents (Azole Derivatives, Systemic). Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Rifamycin Derivatives. Only rifabutin appears to be affected.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ritonavir: May increase the serum concentration of Itraconazole. Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rivaroxaban: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Rivaroxaban.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RomiDEPsin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of RomiDEPsin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rosuvastatin: Itraconazole may increase the serum concentration of Rosuvastatin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ruxolitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ruxolitinib.  Management: Reduce ruxolitinib initial adult dose to 10 mg twice daily in patients receiving strong CYP3A4 inhibitors whose platelet count is 100*10^9/L or greater.  Avoid in patients with lower platelet count.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saccharomyces boulardii: Antifungal Agents may diminish the therapeutic effect of Saccharomyces boulardii.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Salmeterol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Salmeterol.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saquinavir: Itraconazole may increase the serum concentration of Saquinavir. Saquinavir may increase the serum concentration of Itraconazole.  Management: Limit the adult maximum itraconazole dose to 200 mg/day in patients receiving saquinavir/ritonavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Saxagliptin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Saxagliptin.  Management: Saxagliptin U.S. product labeling recommends limiting saxagliptin adult dose to 2.5 mg/day when used with a strong CYP3A4 inhibitor. Monitor for increased saxagliptin levels/effects. A similar recommendation is not made in the Canadian product labeling.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sildenafil: Itraconazole may increase the serum concentration of Sildenafil.  Management: Concurrent itraconazole is not recommended when sildenafil is used for treatment of pulmonary arterial hypertension. If sildenafil is used to treat erectile dysfunction, an initial dose of 25 mg is recommended with concurrent itraconazole.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Silodosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Silodosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Simvastatin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Simvastatin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sirolimus: Itraconazole may increase the serum concentration of Sirolimus.  Management: Sirolimus dose adjustments will likely be needed when starting/stopping any azole antifungal.  Clinical data suggest sirolimus (adult) dose reductions of 50-90% will be needed when starting an azole antifungal, but specific guidelines are lacking.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solifenacin: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Solifenacin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SORAfenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of SORAfenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sucralfate: May decrease the absorption of Antifungal Agents (Azole Derivatives, Systemic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     SUNItinib: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of SUNItinib.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Systemic): Itraconazole may increase the serum concentration of Tacrolimus (Systemic).  Management: Monitor tacrolimus concentrations closely and adjust dose as necessary when concomitantly administered with itraconazole. Tacrolimus dose reductions will likely be required. The magnitude of this interaction may be greater in older patients.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tacrolimus (Topical): Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tacrolimus (Topical).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tadalafil: Itraconazole may increase the serum concentration of Tadalafil.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tamsulosin: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tamsulosin.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Telaprevir: Itraconazole may increase the serum concentration of Telaprevir. Telaprevir may increase the serum concentration of Itraconazole.  Management: Doses of itraconazole greater than 200 mg/day are not recommended in patients receiving telaprevir.  Use extra caution when using these drugs in combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Temsirolimus: Itraconazole may increase serum concentrations of the active metabolite(s) of Temsirolimus.  Management: Consider temsirolimus dose reductions or alternatives to itraconazole.  Monitor sirolimus concentrations in all patients receiving itraconazole or any systemic azole antifungal.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ticagrelor: CYP3A4 Inhibitors (Strong) may decrease serum concentrations of the active metabolite(s) of Ticagrelor. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ticagrelor.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tipranavir: May increase the serum concentration of Itraconazole. Management: Limit itraconazole adult maximum dose to 200 mg/day in patients treated with tipranavir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tocilizumab: May decrease the serum concentration of CYP3A4 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tofacitinib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tofacitinib.  Management: Reduce the adult dose of tofacitinib to 5 mg daily in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Tolterodine. This is likely only of concern in CYP2D6-deficient patients (ie, \"poor metabolizers\")",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolterodine: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolterodine.  Management: The maximum recommended dose of long-acting tolterodine is 2 mg/day when used together with a strong CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tolvaptan: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Tolvaptan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topotecan: P-glycoprotein/ABCB1 Inhibitors may increase the serum concentration of Topotecan.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Toremifene: CYP3A4 Inhibitors (Strong) may enhance the adverse/toxic effect of Toremifene. CYP3A4 Inhibitors (Strong) may increase the serum concentration of Toremifene.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vardenafil: Itraconazole may increase the serum concentration of Vardenafil.  Management: Limit vardenafil dosing to a  maximum of 5 mg per 24 hours  in patients receiving itraconazole 200 mg/day, and a maximum of 2.5 mg per 24 hours in patients receiving itraconazole 400 mg/day.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vemurafenib: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vemurafenib.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vilazodone: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Vilazodone.  Management: Limit maximum adult vilazodone dose to 20 mg/day in patients receiving strong CYP3A4 inhibitors.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinBLAStine: Itraconazole may increase the serum concentration of VinBLAStine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine: Itraconazole may enhance the adverse/toxic effect of VinCRIStine. Itraconazole may increase the serum concentration of VinCRIStine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     VinCRIStine (Liposomal): CYP3A4 Inhibitors (Strong) may increase the serum concentration of VinCRIStine (Liposomal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vinorelbine: Itraconazole may enhance the adverse/toxic effect of Vinorelbine. Itraconazole may increase the serum concentration of Vinorelbine.  Management: Monitor for increased toxic effects of vinorelbine if itraconazole is being received/initiated/dose increased.  Decreased vinorelbine doses may be required.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Itraconazole may increase the serum concentration of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ziprasidone: Antifungal Agents (Azole Derivatives, Systemic) may decrease the metabolism of Ziprasidone.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: Antifungal Agents (Azole Derivatives, Systemic) may increase the serum concentration of Zolpidem.  Management: Consider using a lower starting dose of zolpidem in patients receiving systemic azole antifungals. Monitor patients closely for increased magnitude and/or duration of zolpidem effects when using this combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zuclopenthixol: CYP3A4 Inhibitors (Strong) may increase the serum concentration of Zuclopenthixol.  Management: Consider zuclopenthixol dosage reduction with concomitant use of a strong CYP3A4 inhibitor (eg, ketoconazole) in poor CYP2D6 metabolizers or with strong CYP2D6 inhibitors (eg, paroxetine). Monitor for increased zuclopenthixol levels/toxicity.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F1048127\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Food Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Grapefruit juice decreases itraconazole AUC by 30%; avoid drinking grapefruit juice while taking oral itraconazole; absorption of capsule and oral solution are increased when taken with a cola beverage",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule: Food increases bioavailability",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Solution: 31% increase in AUC if taken without food",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F185391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F185405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose related adverse events were observed in animal reproduction studies. Use is contraindicated for the treatment of onychomycosis during pregnancy. If used for the treatment of onychomycosis in women of reproductive potential, effective contraception should be used during treatment and for 2 months following treatment. Therapy should begin on the second or third day following menses. Congenital abnormalities have been reported during postmarketing surveillance, but a causal relationship has not been established.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048117\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Liver function in patients with pre-existing hepatic dysfunction, and in all patients being treated for longer than 1 month; serum concentrations particularly for oral therapy (due to erratic bioavailability with capsule formulation); renal function;  serum potassium; monitor for prodromal signs of hepatitis",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F1048120\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Serum concentrations may be performed to assure therapeutic levels. Itraconazole plus the metabolite hydroxyitraconazole concentrations should be &gt;1 mcg/mL (not to exceed 10 mcg/mL).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Timing of serum samples: Obtain level after ~2 weeks of therapy, level may be drawn anytime during the dosing interval.",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048107\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits ergosterol synthesis in fungal cell membranes by inhibiting fungal cytochrome P450",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Requires gastric acidity; capsule better absorbed with food; solution better absorbed on empty stomach",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: V",
"     <sub>",
"      d",
"     </sub>",
"     : 10 L/kg; highly lipophilic and tissue concentrations are higher than plasma concentrations. High affinity for tissues (liver, lung, kidney, adipose tissue, brain, vagina, dermis, epidermis); poor penetration into CSF, eye fluid, saliva; distributes into breast milk, bronchial exudate, and sputum",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 99%; metabolite hydroxy-itraconazole: 99.5%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic via CYP3A4 into &gt;30 metabolites including hydroxy-itraconazole (major metabolite); appears to have",
"     <i>",
"      in vitro",
"     </i>",
"     antifungal activity. Main metabolic pathway is oxidation; may undergo saturation metabolism with multiple dosing.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: Variable, ~55% (oral solution) in one small study;",
"     <b>",
"      Note:",
"     </b>",
"     Oral solution has a higher degree of bioavailability (149% &plusmn; 68%) relative to oral capsules; should not be interchanged",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Pediatric patients (6 months to 12 years): Oral solution: ~36 hours; metabolite hydroxy-itraconazole: ~18 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Adults: Oral: Single dose: ~21 hours, steady state: 64 hours; cirrhosis (single dose): 37 hours (range: 20-54 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: Capsules: 3-5 hours; Oral solution: 2-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Urine (&lt;0.03% active drug, 40% as inactive metabolites); feces (~3% to 18%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dialysis: Nondialyzable",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048115\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/17/34069?source=see_link\">",
"      see \"Itraconazole: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment for some fungal infections may take several weeks or months. Take capsule immediately after meals; take solution on empty stomach (1 hour before or 2 hours after meals). Frequent blood tests may be required with prolonged therapy. May cause dizziness, drowsiness, nausea, vomiting, or anorexia. Report any rash, any change in hearing acuity, difficulty breathing, or chest pain. Report any signs and symptoms of liver dysfunction [eg, unusual fatigue, anorexia, nausea and/or vomiting, jaundice (yellowing of skin or sclera), dark urine, pale stool] so that the appropriate laboratory testing can be done; avoid grapefruit juice.",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F10806357\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Note:",
"     </b>",
"     Commercial oral solution is available (10 mg/mL)",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     A 20 mg/mL oral suspension may be made with capsules. Empty the contents of forty 100 mg capsules and add 15 mL of Alcohol, USP. Let stand for 5 minutes. Crush the beads in a mortar and reduce to a fine powder. Mix while adding a 1:1 mixture of Ora-Sweet&reg; and Ora-Plus&reg; in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     200 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add quantity of vehicle sufficient to make 200 mL. Label \"shake well\" and \"refrigerate\". Stable for 56 days refrigerated.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Aronoff GR, Bennett WM, Berns JS, et al,",
"      <i>",
"       Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children",
"      </i>",
"      , 5th ed, Philadelphia, PA: American College of Physicians, 2007.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bhandari V and Narang A, \"Oral Itraconazole Therapy for Disseminated Candidiasis in Low Birth Weight Infants,\"",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1992, 120(2 Pt 1):330.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6074/abstract-text/1310508/pubmed\" id=\"1310508\" target=\"_blank\">",
"        1310508",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Binder B, Richtig E, Weger W, et al, \"Tinea Capitis in Early Infancy Treated With Itraconazole: A Pilot Study,\"",
"      <i>",
"       J Eur Acad Dermatol Venereol",
"      </i>",
"      , 2009, 23(10):1161-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6074/abstract-text/19453785/pubmed\" id=\"19453785\" target=\"_blank\">",
"        19453785",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention (CDC), \"Guidelines for the Prevention and Treatment of Opportunistic Infections Among HIV-Exposed and HIV-Infected Children,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009, 58(RR-11):1-166. Available at",
"      <a href=\"file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf%20\" target=\"_blank\">",
"       file://aidsinfo.nih.gov/contentfiles/Pediatric_OI.pdf",
"      </a>",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6074/abstract-text/19730409/pubmed\" id=\"19730409\" target=\"_blank\">",
"        19730409",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Centers for Disease Control and Prevention, \"Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations From CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America,\"",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 2009a, 58(RR-4):1-216. Available at",
"      <a href=\"file://www.aidsinfo.nih.gov/contentfiles/adult_oi.pdf\" target=\"_blank\">",
"       file://www.aidsinfo.nih.gov/contentfiles/adult_oi.pdf",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Chapman SW, Dismukes WE, Proia LA, et al, &ldquo;Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2008, 46(12):1801-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6074/abstract-text/18462107/pubmed\" id=\"18462107\" target=\"_blank\">",
"        18462107",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Cowie F, Meller ST, Cushing P, et al, &ldquo;Chemoprophylaxis for Pulmonary Aspergillosis During Intensive Chemotherapy,&rdquo;",
"      <i>",
"       Arch Dis Child",
"      </i>",
"      , 1994, 70(2):136-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6074/abstract-text/8129437/pubmed\" id=\"8129437\" target=\"_blank\">",
"        8129437",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents,&rdquo; June 18, 2008. Available at",
"      <a href=\"file://aidsinfo.nih.gov\" target=\"_blank\">",
"       file://aidsinfo.nih.gov",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Heintz BH, Matzke GR, and Dager WE, &ldquo;Antimicrobial Dosing Concepts and Recommendations for Critically Ill Adult Patients Receiving Continuous Renal Replacement Therapy or Intermittent Hemodialysis,&rdquo;",
"      <i>",
"       Pharmacotherapy",
"      </i>",
"      , 2009, 29(5):562-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6074/abstract-text/19397464/pubmed\" id=\"19397464\" target=\"_blank\">",
"        19397464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mouy R, Veber F, Blanche S, et al, &ldquo;Long-Term Itraconazole Prophylaxis Against",
"      <i>",
"       Aspergillus",
"      </i>",
"      Infections in Thirty-Two Patients With Chronic Granulomatous Disease,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1994, 125(6 Pt 1):998-1003.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6074/abstract-text/7996377/pubmed\" id=\"7996377\" target=\"_blank\">",
"        7996377",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tobon AM, Franco L, Espinal D, et al, &ldquo;Disseminated Histoplasmosis in Children: The Role of Itraconazole Therapy,&rdquo;",
"      <i>",
"       Pediatr Infect Dis J",
"      </i>",
"      , 1996; 15:1002-8.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6074/abstract-text/8933549/pubmed\" id=\"8933549\" target=\"_blank\">",
"        8933549",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Wheat J, Freifeld AG, Kleiman MB, et al, &ldquo;Clinical Practice Guidelines for the Management of Patients With Histoplasmosis: 2007 Update by the Infectious Diseases Society of America,&rdquo;",
"      <i>",
"       Clin Infect Dis",
"      </i>",
"      , 2007, 45(7):807&ndash;25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?5/59/6074/abstract-text/17806045/pubmed\" id=\"17806045\" target=\"_blank\">",
"        17806045",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13396 Version 50.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1102-61.234.146.186-71903B288C-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6074=[""].join("\n");
var outline_f5_59_6074=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5708958\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185420\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185421\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048118\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12857579\">",
"      Dosing: Neonatal",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048110\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185395\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185380\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15674161\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048122\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048113\">",
"      Stability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048121\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185476\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185473\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048125\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048109\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048108\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185462\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185389\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048127\">",
"      Food Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185391\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F185405\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048117\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048120\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048107\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048124\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048115\">",
"      Patient Information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10806357\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13396\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13396|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/15/20730?source=related_link\">",
"      Itraconazole: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?33/17/34069?source=related_link\">",
"      Itraconazole: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f5_59_6075="NCI CTCAE grading scale for pain";
var content_f5_59_6075=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F58287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F58287&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    NCI Common Terminology Criteria Adverse Events (CTCAE) grading for pain (v4.03)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Grade",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        Mild pain",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        Moderate pain; limiting instrumental ADL",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        Severe pain; limiting self-care ADL",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ADL: activities of daily living; NCI: National Cancer Institute.",
"    </div>",
"    <div class=\"reference\">",
"     With permission from: Common Terminology Criteria for Adverse Events, version 4.03, June 2010, National Institutes of Health, National Cancer Institute, file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6075=[""].join("\n");
var outline_f5_59_6075=null;
var title_f5_59_6076="Side effects of drugs for diabetic neuropathy";
var content_f5_59_6076=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F74923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F74923&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Side effects of drugs used for diabetic neuropathy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"5\" width=\"20%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Side effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Amitriptyline",
"       </td>",
"       <td class=\"subtitle1\">",
"        Desipramine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Fluoxetine",
"       </td>",
"       <td class=\"subtitle1\">",
"        Placebo",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dry mouth",
"       </td>",
"       <td class=\"centered\">",
"        63",
"       </td>",
"       <td class=\"centered\">",
"        32",
"       </td>",
"       <td class=\"centered\">",
"        11",
"       </td>",
"       <td class=\"centered\">",
"        35",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fatigue",
"       </td>",
"       <td class=\"centered\">",
"        34",
"       </td>",
"       <td class=\"centered\">",
"        34",
"       </td>",
"       <td class=\"centered\">",
"        13",
"       </td>",
"       <td class=\"centered\">",
"        17",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Headache",
"       </td>",
"       <td class=\"centered\">",
"        21",
"       </td>",
"       <td class=\"centered\">",
"        11",
"       </td>",
"       <td class=\"centered\">",
"        24",
"       </td>",
"       <td class=\"centered\">",
"        9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Constipation",
"       </td>",
"       <td class=\"centered\">",
"        8",
"       </td>",
"       <td class=\"centered\">",
"        21",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Palpitations",
"       </td>",
"       <td class=\"centered\">",
"        13",
"       </td>",
"       <td class=\"centered\">",
"        3",
"       </td>",
"       <td class=\"centered\">",
"        2",
"       </td>",
"       <td class=\"centered\">",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Any symptoms",
"       </td>",
"       <td class=\"centered\">",
"        81",
"       </td>",
"       <td class=\"centered\">",
"        76",
"       </td>",
"       <td class=\"centered\">",
"        63",
"       </td>",
"       <td class=\"centered\">",
"        68",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Percentage of patients reporting side effects during treatment with amitripyline, desipramine, fluoxetine, or placebo.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6076=[""].join("\n");
var outline_f5_59_6076=null;
var title_f5_59_6077="Hib schedule US";
var content_f5_59_6077=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F77170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F77170&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Recommended schedule of administration of conjugate Haemophilus influenzae type b vaccine for children in the United States",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup width=\"20%\">",
"     </colgroup>",
"     <colgroup span=\"2\" width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Primary series",
"        <br/>",
"        (&lt;12 months of age)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Booster",
"        <br/>",
"        (&ge;12 months of age)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Routine infant immunization",
"       </td>",
"       <td>",
"        2, 4, and 6 months for ActHIB, DTaP-IPV/PRP-T, or HibMenCY*",
"       </td>",
"       <td rowspan=\"2\">",
"        <p>",
"         12 through 15 months for PRP-OMP, PRP-T (ActHIB or Hiberix), PRP-OMP-HepB, and HibMenCY*",
"        </p>",
"        15 through 18 months for DTaP-IPV/PRP-T",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2 and 4 months for PRP-OMP or PRP-OMP-HepB",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"3\">",
"        Catch-up or lapsed immunization",
"        <sup>",
"         &Delta;",
"        </sup>",
"        starting at:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &lt;6 months of age",
"       </td>",
"       <td>",
"        3 doses, 4 to 8 weeks apart",
"       </td>",
"       <td>",
"        Single dose 8 weeks from last dose for child 12 to 15 months of age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        7 to &lt;12 months of age",
"       </td>",
"       <td>",
"        2 doses, 4 to 8 weeks apart up to 12 months of age",
"       </td>",
"       <td>",
"        Single dose 8 weeks from last dose for child 12 months of age to 5 years",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        12 to 14 months of age",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        2 doses, 8 weeks apart, up to 5 years of age",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &ge;15 months of age",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        Single dose",
"        <sup>",
"         &sect;",
"        </sup>",
"        up to 5 years of age",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     DTaP: diphtheria tetanus-toxoid-acellular pertussis vaccine; IPV: inactivated polio vaccine; PRP-T: polyribosylribitol phosphate conjugated to tetanus toxoid; HibMenCY: combination",
"     <em>",
"      Haemophilus influenzae",
"     </em>",
"     type b and meningococcus serogroups C and Y conjugate vaccine; PRP-OMP: polyribosylribitol phosphate conjugated to the outer membrane protein complex of",
"     <em>",
"      Neisseria meningitidis",
"     </em>",
"     ; HepB: hepatitis B; Hib:",
"     <em>",
"      H. influenzae",
"     </em>",
"     type b.",
"     <br>",
"      * The Advisory Committee on Immunization Practices recommends HibMenCY for infants at increased risk for meningococcal disease (ie, those with persistent complement pathway deficiencies or anatomic or functional asplenia [including sickle cell disease]).",
"      <br>",
"       <font class=\"bullet\">",
"        &bull;",
"       </font>",
"       May be given as early as age 12 months of age, provided at least six months have elapsed since the third dose of DTaP.",
"       <br>",
"        &Delta; For children who are",
"        <strong>",
"         not",
"        </strong>",
"        at increased risk of invasive Hib disease. (Refer to UpToDate&nbsp;topic on prevention of Hib infection for the&nbsp;catch-up immunization schedule for children who are at increased risk of invasive Hib disease.)",
"        <br>",
"         <font class=\"lozenge\">",
"          &loz;",
"         </font>",
"         HibMenCY is only approved for children 6 weeks through 18 months of age.",
"         <br>",
"          &sect; If HibMenCY is used, two doses should be given at least eight weeks apart.",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, CDC. Prevention and control of meningococcal disease. MMWR Recomm Rep 2013; 62:1.",
"      </li>",
"      <li>",
"       Recommendations for use of Haemophilus b conjugate vaccines and a combined diphtheria, tetanus, pertussis, and Haemophilus b vaccine. Recommendations of the advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1993; 42:1.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6077=[""].join("\n");
var outline_f5_59_6077=null;
var title_f5_59_6078="Incidence of absence epilepsy";
var content_f5_59_6078=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64284&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relative incidence of human absence epilepsy syndromes during first two decades of life",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 446px; height: 310px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The five syndromes show developmental variation in the ages of seizure onset and duration of clinical seizure activity.",
"    <div class=\"footnotes\">",
"     In temporal order of peak incidence: MAE: myoclonic astatic epilepsy; EMA: epilepsy with myoclonic absences; CAE: childhood absence epilepsy; JAE: juvenile absence epilepsy; JME: juvenile myoclonic epilepsy.",
"    </div>",
"    <div class=\"reference\">",
"     Data from Noebels, JL, Tharp, BR, In: Brain Development in Epilepsy, Schwartzkroin, P, Mosh&eacute;, SL, Noebels, J, Swann, J (Eds), Oxford University Press 1995, p.73.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6078=[""].join("\n");
var outline_f5_59_6078=null;
var title_f5_59_6079="Current ERT and bone density";
var content_f5_59_6079=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F51367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F51367&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 487px\">",
"   <div class=\"ttl\">",
"    Postmenopausal women who take estrogen continuously have higher bone density",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 467px; height: 553px; background-image: url(data:image/gif;base64,R0lGODlh0wEpAsQAAP///2YzZoCAgP+ZMwAzmSBzOf8AAAAAAEBAQMDAwDMZM39MGRAQEKCgoBA5HAAZTNDQ0HBwcH8AACAgIDAwMFBQULCwsODg4GBgYPDw8JCQkAAMJj8AABkMGT8mDAgcDiH5BAAAAAAALAAAAADTASkCAAX/ICCOZGmeaKqubOu+cCzPdG3feK7vfO//wKBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ2en6ChoqOkpaanqKmqq6ytrq+wsbKztLW2jBAJuroQMhAIDSQNCL0jv8G3yZkIB83NCCcJBwIo0tQjAgcJJBcC28rglbkYBxgJvRYVCBoi5AjUwwgVFgDWJNkaGAj03dsCDRrehRvoKNs1CwcqRDgQAQCFAxOgKRQw4cAFe9gOMGBm0Z7GCBUOsCNIEpFBESEz/zhkUG+aiG4IKupymXHbwpnUDkDLoLOkz0InATATMdTeBQYUGpDDeU8bgGxMewKQ+rPqn6AapiGs0HKetAoJmDGt+VSbRwoJyI20ynZPUAARGCRUKVQjAHJIzdIUAbVsVAZyG7YdLIoq4cOfDCNezLix48eQI0ueTLmy5cuYM2vezLmz58+gQ4seTbq06TYZGvyjy03DPxEZdp07TfvJQ2YUSkAAfLulM2i1gyfZCiAkvYwNm7VEO5tEAgHQoX8TTh3HybcAdic8EEzaRgwXSjyPLrC6+RrX9wK4QGGCXAzZMQjArQL6+fsysjZcuLa4tgwykaBcCvbhZ2ALF0CUQP9F4fVEDgYWyNVNBfMpVkKBB2aYQgMVTYBMTxmEdAAF9FhQ0Vz1XaPhikZgyOKLQbgI44w8yEjjjTfYiKNkwwgQG3BW6LjjYwlSgJQFQFYh5JCNJZBbBu0lScWSTC52lEpQSjkFlVUilkB42SETpIpdlrkCl2YeloA6CCAg2JZkpvmYXL8pGaecjTHw5ph4RjbMLsXA2Sdk5NQ55Z2DHjZidGJKgWaiP7mZxaOQloTBRm3uGQWllRLE0TN2dionp6KCU0FuRyHqBKmlJnPAcRFo+QSrrdryqgixhlprWxXoyZ+uu1oFwYkUsOaoqsGS1Bywyd5Ia7OuJGUsn9CS9BD/AxgEymy1Y4wX3bfghhvddFxAcClEGkwLxbPcbtmBAvDGK++89HaALBapcQSeoO2SIYACAQQs8MAEF6zAvVpcEBe5syLc76QAFyyxxAefoW4T7D48a8QTdxxwxV+o9q226zqscZAcezwxyF586gzDq5p88pQpq2ywzFKso4ubE3B17Mxg/Gtzxyx3cetT78jKRMZAKyH00BTjHIV7AsRFodJLMN00Ek9DTXDRXETYDAMQRNBfw1t30bXXAoPNRWwwbyp1ld6Ka3e4cS9dM9tuV6L1jAJ4sMDghBdu+OELeDC3EGuzHUDflPwNowALDGD55ZhnrvkACywe495eQz6J/+QvUr756Zt3viXoUIuuxcUl12o66rRbrrqjrA/tehYL+nio7JXXTvvtm+Zu8+5YXMAMA8fJDbzww3sORON8Sy+FLvyWOjv0qVvvA/Whe6+EfGBSq33w3GtO/LrGq4w8FRxV0OjPrW6fPubrb+z4wO9TYcG5eirfC1KzGhNcwDWNGk/e+CI+wKHvfpfL36ra57H+TeF/zrAQC24zIt3wRirkaE85CNTAyT0QgpwroQ7A1zoVGoEjSblAAzTFAuIYpynJOQAAGpAQlHBnBHUrz/lQiD8XWoeCRDMiETAQAQHKID1k0k5IgnFDABBHBEFUYobsh0IJYgyJK9OiEBrwDf8LNA8GUORGe95Tl29IQ2mkYxEXIehFve2vbWIMQnlylR+GwEUkJAhJAgCkjV8BQD8oiOOK5ni/OmYNjFHzgjQy2EMZJGgCC7LIVKDxILFd4CgMaEADAONEbOQRP4xMnyOdBsmbeeEXDIiIPEj2Ag5B5EM7ERGJRAABEVWAlqZ8HhFtd8ontvJrxfQBGSeVTPOkknurTAILdddMHQwyF4DaVqWeCb1ocu2Y/KtmDrThMqwtTZzC4abwvHmEaR4PnTmS4bfmF7v6nZCO8DwTOPEIBlGGCD7ahJQ6a8fOFu3zY/m8wQTy0Yyz1XOIw0zh6u6IUDBogwJuMmfWEnqagUb/b6IUtWAUGGCQ+QQ0UR5FXUGL4E73cbQGC7koQLMnqpSebqVEaGkFX0qDDGjAAhkQADBjJsxh4nQIOk1iGLC5LPpB1Kg8NUFSwwiGmILqd/aMqERxR9HHRVUGGmHUSQdl0+6B9I4ihcIEvpqiohLxqIw7qFerioBsYvWpb2UrNuSa1ieUc6x9Kqv69MoXvhLWBSKDDj3RltWIwvVzXe3rE2JDWcCCo253y+wCnXbPRh52qpEMWTOcREPGVkUAH3CAalfL2ta69gOf7awqP2tYMEygPc/RqNMOGwkBOKAAwA2ucIdLXAfEVquPnV5tv0DOBPCRpj7xLXGnS13jbkm2/9CkbWR5y4IJYIACAtCTZZUhXeqaN7jWdRR2u6ndkHJ3BQgZWylN+5Pynte86d3UetfZXrS+dwUQEIAG5kvf6P72vvg9rmP7uz/JLkE2doVuSeyL4OIqGKpnbfB/T0DJq0qYJBSusHDzu679EpTBjnPwbr0LnQmUlqhWCbGIgUviWZn4o1x1r0W/IQCffZggMp5xjVd1Y5WiuHpgQEoCLIDR8SYjyCIeMsaKfNMjh6+fGTyj8+yA2czebbPSPPCMR3zhvGY4xRtOQYCFaj46CGADD4iznOdM5zo/YAOfFfOYaVzmLlq5hZtQ5BYE8AACGPrQiE60ognwgDzvmczXRf/un6kZ6DR/r9CLzrSiG70lPe9Zykujsllz7N9K34HQmk71oTntKE+PGdRZE/Vgz4xkTQhaC6hWdapZvSlXC7nP+KT1lbvQpmJnyslqyLWuM83rdfk6ysD2rLABbbQO61aalu6Bspe9aUc/ms+RXvC0KW3rbNcI09zudqe/DW71Snrc7wSDT8V6VzejO92Ibvasnl1hWHP23aTWMBhE5GGn2hvf6m41uwvgb2nKOnPJ/QFoXcncmwjR4NHwssbBzLV7I5zR3v52w7n28CLC26U7ZgBMLCsADkjg5TCPucxnzoHPehzh+l4VvxE88naWPIKTjvcXQlkB91ybawgTgAT/DMD0pjv96VCXgM0/nu+QP7rnLfo5MU++0342YDdkY/nSoU52skt9SzfHd84xtvP7Yp2lWt9q8bbrdWaeaexlzzvTz+6otKd77Utr+3nfntO4R/x7y/WCOuxeH7zrvex835TfuQ34rAk+weHGcMDR3E9M8kLsj9d75Nc1+WVX3mmXr260Z8t1pX7hr/U+gdJDn/fRz6r0uj59mBdOeKQaPugoD9k8QU97s0+d6obWPddSP93eM+73raeqvAc5SOIX/+m2XxXuVa38djLfwpk38+Zr7QUeXvTFLCBgA6Z1EdkAAG6fJ+Hdrx/14yO/+y36/nCdHyPoj3/YXnBbmGRS/zPAQbnRFBnkGwUnVUnnePRnANmHMdu3a1b3aauXXdEXWl7QXM8FAzZ0NC+hCwsxAcsRf0D0LRcnew5IfxG4NBOoafjHUvoHae4mbv9HbQH4XeGFfvXhEtgxAhXRHRqBAPviHCjYgA/odC2YNS/IbBX4ahfIXhlIcV4QXxpBYGfig+ohAjxEgvFRIQeYSEiYhHtnf1QXgzk1g+gVhfw1hci0VAKGhSuASIZEAkFoAgMihvNHhhBohh+Hhkilhu2mXwA3dzoGBkw1VCtwSZnUIMCRDV74FFejQcHUeHzYh2iHfMn3hL8Wfn7mhuFUVRl0dCZgSx4iAiAiF81jIs1QAf+ww0B7SIZL6DRNuGiAyDiCyHBseGKgyE/MRVKKZX1JOIvSVIsJ12u8t4s4Zoil9gVrxXgEsoLXR4wdp4kgt27sxn/T43/MKHBfECsRhnFSJY3FR43tZIyJdosxkovaKHHcyD5093qjKIwPaI4tgo5Vh40ip4xG1osVJXz09mPYQI60Z48shY+rxonQ5onBdoPklglcMnt8aJA5hZCbqI9Xx49V5o9zZTRhMY+xN46XSJFIZZHXqHDZqJGj1o2cR2xlY2w8uFGxOIx+iHMK2W8qOWsOKXQQOYayWJNqd5M8l5MQB3xd9wXzFowheSEEGXokyTgmqY7Tw45EaXI7GXz/AQiSAskXTfl4TxkjUSmUbleVQMeRKrYECRGOWxaNIwmUfyeWg0eWW3eVR+kFETBTbaaCbZmJmiiVEkeVDCltdOl65aeV4siUe9l31uiX3wOYNah5LEl+RoMpkrKU99CVoueWlAeXmPeY4heZANgFz4gFEYmZtaeZpseZqheYrDeY0meXa6WUW/kUpgl5qJl7qtl8cil38HiILWOYa5lItWl8fHl/uQl+nvmJrqmBXcBUTRWcejmRt8l9x7l/u3l42pZ4mFCaiSl5i1mdNEiINgiaOLidPkmTxXmG4LmGrImBy0mF5jmT9TidFIiRFtieUvieb1hu8smC9AmD6zmI/yVWiL3ZjK/0EAviUAUmktKZnn8YoLqIn22on6H4BUbCAM5Fii1ynvPpoDZpn1AoobxIob64gUiSW/Tonx4alCDaicnZkOT5kF3AAAFhIngJnQz6kyv6li26kC8qmDHKk2qTQRyHbf05jf/phD2KkyK6jAXqjV8QEPOQlzmKnorZlxDajt/zjvrjm6+klg8lnN1Jet+5pEPZpP1Iov9ol8AZptGpo1dqnGY6lmi6kWrakRsIjK9hmQM5prdXpii5j3W6kk/akgGYZtzZoHGqnnMal4Oqk0GKlV0AjiZ4mJfpp9oHqMiYko9alGZpbiQAe7MpkXDqnVjaqJ0pnpBZqP+SyQWJtaejOpz1t6Obiaqr+aOtGal1GZ+WqKimKqeBmpGdapW6SphdECIfQaWI6atkeqrBep+46p7F+prEphMPwV2JWqrNCqybKqjRmp/TypxccDQdiKPLqq1/6qzdKqzfOqHhCp9cQFLvVwE+Zql9yqzpyq3OlozDWpZ3epZKYFUgaK9ciakSqKn7yqntOqLvup9RKg9aZq6Xiq+Zqq4J662q+pmsGppeUFkpiqS0mpq2qpv9OpcNW6FdgAFgIRdhx6cFS7EHa7H7xq8L66RdaqBbYH6AwQw36qZV2qGL+qAji5wZq5wnW6KDhkkuBhcaylIcqqJB+6HPGqI1m6b/R7umg4YWFGAO+vCx5Ziktpil12mUxopr1ua1BQm2x3ix7Fq0MLqx5akF8QCTPaUa61cC7bcLL+EaEXshTwuyUcuiU+uibgukcCujdmCAF0JJ6/FBPJitVvqrjDq4Plq4uXq4QloHH3hG7TeCf8QOcvGKkAu0kiu0lMukVWunV4undpBGJnCHYtFGRkge75BZCOByM5e7ucsBtatxvvu7tgtndja8dbYBvQu8yJu8CJBartW8zfsBx5u80qtxCCA4iHO9h+MB0Tu93CsuCPAu9BK+4dsB2+u7RUqaWngnXUgUThG7J9i98Bu/8ju/9Fu/9nu/+Ju/+ru/wHu+V0CH/4BUAnfoH/TwEIqYNpHBiAyySXwBESPAQ/PgwAisGaaIS++niiQQFyNywBPcwR78wSAcwiI8wsGiC1jyJWvAVK/4BSrcBQdUQGbwwnfrE63YEqDqAi6zWBzWtC+UQTqMhzycA+a3gDtAiTwwxEZ8A0lcCS+DEfHADgG2Dc/RC2viJirxDwGWM9oAAXZRxevAS/ogP10oAHK4BGLBxSzhxSNhLvIgShBBxkiQIBiaHdSwp6+BxXX8ddQQVBC7HgJgAbECD29cxjYgx9uQxXYcDHj8FHr8fvMxpd0AyAIxxoQcCSMSSwhBDQsBEiKRIFwREhewFQvBFRqRh37lFMohAP/ywQwNUCSqrBBDyMFKELupvMrc4coquxAbIcs8gEgCAhw9Uco6JMwrIQAGPEkIIBczFMtB4MsjIBXBTCdTIc1GYswHkAvPoMy6TAydoBM8xAzUEEvQ0RPMkAEb4R8tNsxhGAU8GxLw4VOnMg1c7GLpwsBW0M4jBM/XOs9moxJLLHFbCM3Q0EGoeIBc/A7k4A0ukcn2HCMBDcwDHYYEfdCqPA32wND/PAnk3Aw5EZuvwUPkEAzgHB0Nzc4j8g4qYSQakBXUgCRykRsZPcsn7TsqzdJWlMwdFNNHTBWOiIoDDSRS8UbjYg8eEcQw8M0j0NMMTBVBrRND7RJFnRjQMEn/1BAS3qAa7zc2KpEVYPE/JQ0F7ouKmLQQ3gAhCQAYU4FJlYwEYZ3WzmXRZo3WCrLWO1AR77B4geEODU0VgEFGGkBGUO0Scy0Edt1j0JDXwQzUQNLXCfDXRC3Yat3NwJHQ7wdA1/Ag2HAipGzUQNDW5gfO7NEMFNAL2XDNVeDZzzANob3BZWHacSwiC7VDgLEQP/3MQNJLzTABFvDYddwMvFwDFwDb7DBKepLYtm0MsL3bgd3brk3Czv3c0B3d0j3dtFGuVzAMv50F1o0G2N0uQzFoTmECGLEF3y3eW6gFQQ3HtpDI7xcr5fHEfrxkwZAOROi/QsDHU8q0RNgLqnFA/8qjQxYAx6qxwk7jFPEwpe5wDfB92jqk39lyF07tyH08BD7VJlCsDxGgEpEcyDs0yM/xSX/M4YzMF8GQAbHy4CM+4mwsP0wM0QBANRFAgpscEhrgHd6cED2mV9VswC9eNbFUF3LxkR0OupHoKE4xEQzyEBHxR5ysoE7w3WsVFySo5NCw483d2QwRF0cBXkjhGzi9zLsMFciszPbcEzuucmWOALhcr5bs4oBBPgAgztlQV350SIvyw0hA0ZSdoXJRF3QxFOZMIgG8JU4BEzKBEXKu0z2MRbHS5/ag5+fNA1wMUAd0KwuBzS0t2I+oF5meExDNxQ2BEOwg0Pxcz5Qg0P/ZUXRX+MaKNd4VUudOINTSsRVMpkPl/d0hdAAEXuBfghRKweliHZBabEUJUes23BK9a98y4OpOIebLbc/OTg1RvUm8neY3/dKVgNjQAAwfidtXrdDXoAERkAAQPFKh1NiqoRUVURcj8N2TxOabohdgIRZfQQ9WTe7cNRQGwYpdQQ+M/ddDABhmNNpp6R7H7hFqHe3Hru1xjkkh0Qvanha7jdaUQNy07R+3VNksC+4iwIooAgW4DRFApeTrfusN/uIDa+TbgBcICuQaH1YM/n4k3+DLk+q53beSLiLQYEujffBaeM0Kbw8W3xMQoOTIMPRq/hCsPSM8UeTUvRk2/fT/Uj/1VF/1Vn/1WP8G/RDf8dHGEj6lU7xMAeEmdP0DW7/1K17ij0wPYb8NY99ES3D23mBF6mAO66EPD972Jt4mUSX320Dfdn8BeE/FQkVGe5+C5sHba17MBpwNclHREWDMyt4Dir8oKsv4QF/KkC/5D7bcEJzjWx5eLOH40wDjTp8EvP35FBL6aE36FEFSMX4gvF3qGQDp43wcIUEhk0/5y037tp8NuI/ju58DvJ0V4BUMWWHLz3E0b67eTFD8d27nyg/8ItD8ZT8a1e7SIyLr3tAXla30OG8E2Y/TaOHU0uH9GfBdzRD+QlDtrx755RAd3RDevVQRaP78z/7+2SAf/9ABApdwJAAAVdPBXKb7wrE807V947m+873/Q1YCxEGQwFgSDAZg2UhoGqMSAKNJRA6aHxcWZAyLx+SyyXhGpyYrVtvlfsMCTSTROFSClGQEogYgPBFBvHXFEc3V3eUd7GH5kZgEJgwWWl5iZmpucmVNYBRdUBw0EqKQTlj8CTCsRHDyeIIKiJJSmFagqkYCsLrC4sgWWajgZQBYjDaK8OYeTDQA5wgLEJNWHCfbMlM5Q0uDh4uPk5ebn6Onq6+zt7u/w8fLz9PX29/j5+vv8/f7/wMMKHAgwYIGDyJMqHAhw4YOH0KMKHEixYoWL2LMqHEjx44eP4IMKXIkyZImT/+iTKlyJcuWLl/CjClzJs2aNm/izKlzJ8+ePn8CDSp0KNGiRo8iTap0KdOmTp9CjSp1KtWqVq9izap1K9euXr+CDSt2LNmyZs+iTat2Ldu2bt/CjSt3Lt26du/izat3L9++fv+2TEDFB4RAsApHA6w4BykuCYrAEjF4MeUZjV0ISJwZQIJqFbANifY4AgYEFkxEQIAAA6HOEJ68gFC6QgMRFlKflgxAioXPhHar3lLZ72UTBxAYRz6CwSjmrS48niBgFCHpERhM6LUCsokLjQRgqBB9+gEIjwUAejYqe5YIuYQP31scwPHk2kvUn3IeGWQsCFppd1psz0SgQQb7WSD/BmREmDBKE9KNgFx88h3wQn30KRdJfiTsd16CFWhzXwwW/NdIhwqix2B69EG42YR6kSKAjE0cQNqG+GUo2AEYJEDdCNWoIOILYyjBwGM8UrefigzmYoQUL8JISmMNLJFFjhje91grZwCQwXpB/uFCLaVEt4JoC1a4YgYYbIkelG8Csx+cc74jJ5134pmnnnvy2aeffwIaqKCDElqooYdilMBvMFygQTUmHCiYoogCComEL1ywxCivPCblpSZ0JqOMk1EaHxEXvpDFFq0caOKkQ4o6hJulvvjYp5JEQoSODKzWAg0z0lorqi7omp6iGIRBQQ3ABhufrTHkchp1FqY5/wOzzVIGgQYmHlPfIglmJ0AFYdwKw7XYKnYqKTii1sotyBSDzbKzokvrufWG1QACAhxY7jv34uuVdxQwR2I9AAfMVY9dUjCBv+4gnLBWmR7j5cPtRCxxVgn4+trB9GpMaMYhb1yBagi8Es/IJF/ViqfyrMxyVQykTE/MMk+lr6SL/gsyzlqB8rLKPv+M1XcyJgbPzUU/hbI9SzPdFJsn19xz1FupOyzERF99J9RdJ1WBsplyrc7XYB91gICpwVw22k6pjdrF6Zz9NlEV0Kxq23ZXBUExFBwzNN9Wvbr34HTWfXhPFDQQuCWFY+qogAA0+ui8ij/VHGtvWBpDpszVSP+5pqH/6jbmRcnWygQG/nBquXqzCvsBjseQ+Ok8ZaAvKRj4ysOzMBSra/C8gBrrvrdLdcF1pObw+wvDU5Ir8ZwZbzrySdGug/MuRAsAdd1Pa6311wMlRaw866Att1h++8xueIB7OflKZb1uD1mzC8B1pbTLf+nz0+8KlIjABCqgtPEBkCdx68W+5mYO2yVwJhMAw3XG5cByQDCCMbGAyxgAgQIdUINHiZTNEChCuWTwhGhJoQrNwsIWsiR7VoPhUBIgHRmu44U0TMkFiMCAyWHMhDu0iWBCOMSeIKt3hjviTk5Fm3nokIkisQCbXKFEdkRRiiChopS0lkMhalElp2L/3AUaUDUsgjGMPQhVrNroRjcy7x4YiMAVjahGWAigAwrYIx/76Mc/diCN64ANMoC4tTsCQwAKCAAjG+nIR0JSAYJUx/H0d8EHThKRN1AkJDvpSUnuo1NdNKDgNLkJTnoylY0EpT4Kgx3V5GGJpsQEKlWZSlbug5AlnKUmamnLTuISHwnIgHl2JkteFsKXv3xkMO9BgqxdEoOZRGbtFrlMYE4Tg2WMVdJmSM1kWvOazMymORrQuApgAIrk/GYvwinOVa6THKsLGnx4kLvMyLByv4mUYNBnrnhSU5nvbCY+SEABlEUzBqMggrJiswQVnEaUXnxBFmcpUHES9B5gKMIQ/3zwIQB0j3tq8052HkOBfsqPnV246DUzao8sGDSdPfiRduhFhNM0Rku9ggEbZaXSN7B0mS6tRwY0YIEMCMCfOKApTV1wB141RjbJ4mn1frpSd74zAEOtRzEhp4NtvUJvL1DFHW41n9oBFJlB/eVW5wFTUiQUU8+w4QFaUJ8LWEAbpxEXuVJq1ZlidaBpDYcQkPaDBqjgG1jq1B5MYA1j+PWvO1irLdsqD+k8bbAWDSxGNSuN1BizlJLlAWVVadl4QPOY+OrpG1vbxjjSjbMt9SwwzGdY0SZMAB5YAG9769vfAncBHqCtD0p7S+LC4kDKVW29BLCAAUA3utKdLnUHsP8A5JJWtkLFribuYNAzBjFkzq0ueat7XaVpl63czcQEGtaZuIqjongab3nrC93z/iu9lV0vJp7pH+aii772LS9+IaZf0/L3Ep+gACvAi0bxPnfABE7wJg983H4kiBQsADC2BCxh6hYYYxb+JIUt4QcN1DG8GvPwh6UbYiyOGJuhlFRo7ZjbCLd4ui/OYYwjWWIudFFoNg4Yi3Ns3R//qsfj3IeMPtFkB38RwkbWMZKtpWRHnhYevBAXh5tV5Bzv2GxXhmc/mJOAZMA3HPL1Go6nfGT0ZhXLVT5sFw2pYol9ucVhjm2cydwPPyRVnVJ2833nXM0+MzLLKlkz4to85T3/o8O4JMYJo+eU5w9D+hySlvFNKg2nS0s40w8cc6INrRBPvwnUAxY1BkmtVVPr4GSyhrLZYN0XVduX1eTYtI/3EWS4djlYuK6vrsfB6yV32tZ8GfaE4YxoRbujqKLq5iFX7GgjFzu+roZ2O5wBbB/cs3Gec9SiKmfnfw6a0NlW87aVzZgsUGKSC22EFx4at89tKrL4YjZ51w2OY8u5HyRgQUd78NGQmiBaJNWfG1j1P2sTutDO7jO32XGGFPCquJBpKq5wWiHowUpUlcTztcHsboD7OZcNgMASlLrJjXPHBE89lbFq7oKejvzGEX9zfhH96n6Y8w1gZXg9kZGZ+oCv/zwPJ/nO/S0NlJe6HyZ7A0npalfk4FWv7wOR+5au84g7PZHtBvoEaswDxD4jMfVh7OT29y6vE7nkej752PmRWtzGvel093nFB8nNYNtL7pje+7PdnQPlDhPwpeK3eQlPccPfwLs9ojXdII8XxoPY8XHuuzraW/aCD3nfgg+15rPK+XT4l214F73eJ755y9dgwQ1WPKUwT2XXmx72NMjwClIcZYiDvfSC9ceJff97pgcf98P/s9mrLRHWujb6sKWJ7V0s/M72460TPX5EBLCBB4A//OIfP/kfsAHdE6T60Q07HuvuazDcNvQOEcADCGD/++M///onwAPQPxD1S1zPFf9eP2DWx1AE/e1fAu5f//EEAPKcgfGd/8UAaKHU6s1f/SlgBtofA+6EA7IfJ0Ddz9ldF6XZv0lgJiCgBmYgB+qEB17fbAHd31lgQ6SgCiYgC+aECyof9iXbAWKgDS6gu0Ff9L3R9Gna6K3aC26Xr0WPkHlT9/0gEOYfDmLRBzjAFWJhFmrhFn7AySFhrimheu0DAnzQrNGeQdSgFOIfFeaQAxTAG8JhHMrhHDqAF7aeAD4epZ0gLUWhGm7gybnhHAqiINah0nwhsYXhfvWDtMXfE0JEGvoh/wHiIFJiHBbivxxis+Hh6xEgCZ5hQUCiH7Kh2QRiJVLiJUJMJvZbIiL/mMCJRwXKHw32oShOoimeoh0m3ybmXvbJ1C7VwBAS4WspzSyq4SjSTSnaIh3iorqx4oXxg3d9WyxiBgdIQDVa4zViYzZywMkRoxQaY6QhYzJa4jK62QeekvvpwwpQTbAJgAQYwDvCYzzK4zxKADdG4hrWojjKISpijCo23g7CID8UYBeEWz45SmLwk1eh27K44zw6pEPW4zDe4/19o6aFoz4WAD9ikT9mHkAuIT8Q0LT9wLw1lAuwHOggh0TNzci040O6ZDxG5L90IxBW5ANdpD5qZA5x5O3p4vKNoScaHB6A1AKZwAi8Qk65issVpem05Eu+ZExCzEzaYE1i0E2K/2NOms1OWp9HiiE/dJVCLhXM0QvL4cEBnAmv8A5ViRxTNqRTPiRUYoxUqiBV7ppVJiNW0o1Wrl8zTlpFMFXMUU7DtEI6SRVDqaWM5JwMNKVbQqQ9TqQkKo1d2iJeRppeBiAEDmBFDJ1YJRwJZIAKTMZZLeSvtCVjyiNcYpFcaiBdGptkmiJlHuEdYmYeVkTVqcDVVcGOcFBd8RURrCRbmmZjSuRjsmZ8uWYlwuYDWeYDilgEXgTaKVZ9ZIAzNNZjyQvc1U5pBuc7omYOqeYK5iNGvmFyYtBymmMvoWM+QMAo2FDR3Zm1aOd2dqfZfKcCFqeaHectGqJsNmdm7gPBGP+J6kljUcZncM4n3dTnDYaneJLnrpknX3Kar5HIe7FjgZrmgUZaggZhZIrnOO5nLs4mJ/IDA2iAaXxChW7naTrmRN7nv+XnIDaosT0oVyoiP4yAlBhhpAFnisIjhmqahupfiz7dixIiOT4ahPZaP5QoiAgaQ/Joj67oPQppIhGpMn4oM9JoKzIfLDpidj4pd0ZpJE4pHlXpPhoptiEpsu2D9pXg0+3ok/roAwHpFC4oRsZofM1oT/Lg+4nkDGKGhTJmnGLQnOIjh3boeJ6pyWWpM+7DQDYpaX6pAQjqrhEqRdYpTibq3C1qX64pAjTfeyomoLrlpBpbpf6hoR7qnar/WZ6G6C6OoBM6H3xGKqnGl6lC5r+UqYdiIn/CmHM+owwOaC+IqlPSqprZ6piCYK7Coar+G6v2J23aBEsO61OGKS2iaocy69M5a6/6pz5M5y+g6JcW678d66VeZaYO3qZGqD745ihAnrTOarUWo7neJbqSnromqYTKTbjCqbx6I71Opr0mIb6qqT6AQZd8Br/y6Lg+XbleK4MKLBgSbMCBZJ0pbIoybCI5LK4eKqJeaTmmKcXyw5Ke24M5qbj6K00C7GtGLCJObMrxw3JdrHym7FSuLHK2rCa2qk/mQ3gowQooZeXZwGIubM3O5c3q566C6LOKaD541xIQQS92qblM/6tLZiwebSzEKKvHKi2W6mlA5oMAlN0EhFWbJtKbFu1wsijSwmjOruLLRp0+TEeP8EhpzKyBGu1qsm2RfuyRwq0Ihu2vmS0eoS3G5i14Pqyduu0/fu1HOq2sqQbl1UBBjpuLUI7kDG3h0qzaSuneWmnXguzfnp5AkGS9oaTogA7lwSvKcq6Yeq6Z9i2aiu4eZsLBEaV2HGWFyA4OLeXQVu1bHq59vq6upiKv8pivHqBYOlRZRgPIiY/vxmvrWivHdmy2JtK2Hm+3SsRf0osoTNCO1FyxPO/J9qv0zmviYmrsKmrjdiVFbKYbiNQwgWbS8QzO7Uv0IQA1ZuP+7i8H3P9vMAJwAOPv95VfAZPfBvyvACvwAiOAFW7hAz/wByTwAlNwMCLAbgVXBgOXB0xwBXvwGyGAHv3RCI9wB3QwAOfoPdhmXWEJKCDBc7RPdoTcB9NwDdvwDeNwDuvwDvNwD/vwDwdwCt8DdKodcnxrI6yNuwTtaDFxEzvxE0NxFEvxFD+EYFQMxyBEV/HuliZePlSOuA3EF29xVVwDZwAmQWQNtdHA9rFDGjPG4HIBNLLxG8zxJcgxHK8xHpMEjsqJviDAFvhBCbgGZ5hMBBxDZvjBO+jKFxBycJiAbCAAbdyBdBhfOizyCjTyHz/ybJjTM9BCOXiHkZwAerjIZiAyKa//HHogVSTnRjWkBnpM8idHxgqUQCKXcjScci+kcpcMAZPaxiu/DyXrRCNgR4KgR3u8h3cYUC7gFR5kgQFtR7W0sYZUCHiEQW18R3hkAa8s8TkUS2NYMxFgM4Npszp2cyYMnYVISH1EM324jPeAQZLAVSuYkTkDQzq7wIWw8zu3M8GQh3nMs1luMxkOcyAcB2Rgh4zUBxFkQMY1idhWCL3BQ9TmQjoVldgUQRCQLevUsSXvSEV3iQZgdFIRCEfrMWmdsT4jh0TTR0MFwb7MAoJARkcDVUqv80qXpES/NHigCH+gB02/xELHCIuI5B2AQvNy1IwA9Tgw1L4cA8FowLag/weJuAuWzENT8ws8RzVkUDW9LTUmlJWYWDU7X8qF2Iqo6Ah67MdX+0BYd8dYr3RZS8hZj8qJ/PRJi8TaDXWT2IEqa9gxbIt4UJFVK/L0zFUWGAESFAmLYDFqGXbZITaRlMFcVTInqMC+TF0r2Ehc5/OlOAEUPEF/zHTZVfYbXLa4IIdmgwJn24cJfHYU2DVjl7ZLXMgsdEkVHWxu9iJECyVbg4P4yhxchYIyvMuNnnM5APf7HDQtEDchGLc5XIA3bAGV0AxZd7ZJekMSiDYpk8Jx/0B0o8J0V4l1t/YJZHdsPzcVq/d6s3d7uzelCKg96It310N8H8R8R42K3EOYDP/JGdeDfvOUf9uDWcuyVNxyl6RGJfnxFkiGBURDb6yGEIfDKjOpJa0GIUhBo/RQhahCC0jBGGtaJPgxk662myz4VadJgm9OifMyK094iWoyJBsy5bjy8cQydNDCL1fSgWdAamyOLhdlNEDyE8WESgPABAkAATGce2iBlhzHIvCVO/jztFgHdqRHK0TP+6yKDCtNJFRABEB0LTjMkr+HPKhIlWfHeiDHlCudNBBBBFxHpjAYc5jxcdDzQEOCjti5WcI1PE/Hhqn0wIAHKcGEkS9BEj2IQnsq6WwLg6kxOuy0bfsHgDA0rnRJwcBvl5eACCAAaMpJQkeImafJpFfIfkT/uoBjQhDIVKPETRYA9FTPtIToB1fHenIEwSskyBaotEYXCIifhJGjgAqwgCcjjZ2EAemsA10bwYeEiH6rCCiMgq8/EAnIeQOAQlobR4s8+jowCLM7yIn8r4T/gLFHwqyrda1nyXbDdWwbeVeX5Euo9kILQnnwtRTICR3YgVC2w2tLwTAEibOPehnDDIfgQfToCJPWO+QxyI9YgxkzKb+DwxLk1S0U/ASZ8bn/NGmb+8XTyGY/SALkAiHEu6cqdhnEBHVbyVCm3W23iZxYp7SHwyk8w1F9ycdVi35DFBRFAiiATgn4EMsLgagzzDMEyZWbty6Ag8wjB9q9C3p398bv/wfK18d6rvxujDcCjMnb+UkGdN17R4VUe33Yi/3Yk33Zm/1D6IZuDHk0UHhEJRVswDgdrUPaG8EJcHKLM6lrwH3kzvYm0H0JQDiPUE5pbI7eD1OCG9rfI4PJCP4FEH5rvP3hqwbtRoVdC3p4+LmPbAdPg/lJJft2X74BsTkktALnzy062DWUj4ucswITLEcRILmSq0Pq4wFfsX4ZvL7YUhCXz4ld87qBnLpCC0gujIu4w4LvlzQxHQdPC39nFn862HWjb8a2IIuujICAHHqBo/52S380UH8YdMYCZX/fK0Zsu7uyhz8VrIkylOw4mH+JnNTyj8ofrD8ptL80oPepgP/5jogKCFzCkQAAVE0Hc5nuC8fyTAPJIdg4ICDHERlhBEQRyYRSsWrMpvMJjUqn1Kr1elr1cAmMJcFgAMKNhKYxKgEwmkTkoMFiIVqfoPsNjxnlc9rE5gYnR0XHsCWgEZHQcFBBR/EVAfEHgFDmA0FYZYioyOgIKUl5ZIl5oLmpusra6voa8zaBgXNB8UOhifIzYVEpwLASAQslSytgi6tbwetbCixMzGSMY6HimAFgcXtAYaTGfDDRIN1ELWD9U5G9jfttEj5ePk9fb3+Pn6+/z9/v/w8woMCBBAsaPIgwocKFDBs6fAgxosSJFCtavIgxo8aNHDt6/AgypMiRJEtDmjyJMqXKlSxbunwJM6bMmTRr2ryJM6fOnTx7+vwJNKjQoUSLGj2KNKnSpUybOn0KNarUqVSrWr2KNavWrVy7epUWAgA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between bone mineral density in the hip and lumbar spine according to status of estrogen replacement therapy. Bone density is highest in current continuous users and current late users. The values are adjusted for other risk factors such as smoking, exercise, thiazide diuretics, glucocorticoid therapy, and alcohol intake.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Schneider DL, Barrett-Connor EL, Morton DJ. Timing of postmenopausal estrogen for optimal bone mineral density. The Rancho Bernardo Study.&nbsp;JAMA 1997; 277:543.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f5_59_6079=[""].join("\n");
var outline_f5_59_6079=null;
